<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Neurochem Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Neurochem. Res</journal-id>
<journal-title-group>
<journal-title>Neurochemical Research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0364-3190</issn>
<issn pub-type="epub">1573-6903</issn>
<publisher>
<publisher-name>Springer US</publisher-name>
<publisher-loc>New York</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29616444</article-id>
<article-id pub-id-type="pmc">6345729</article-id>
<article-id pub-id-type="publisher-id">2521</article-id>
<article-id pub-id-type="doi">10.1007/s11064-018-2521-z</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Paper</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Magnetic Resonance Spectroscopy in Schizophrenia: Evidence for Glutamatergic Dysfunction and Impaired Energy Metabolism</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Duarte</surname>
<given-names>João M. N.</given-names>
</name>
<address>
<phone>0046 462 220 708</phone>
<email>joao.duarte@med.lu.se</email>
</address>
<xref ref-type="aff" rid="Aff1">1</xref>
<xref ref-type="aff" rid="Aff2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xin</surname>
<given-names>Lijing</given-names>
</name>
<xref ref-type="aff" rid="Aff3">3</xref>
</contrib>
<aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution>Department of Experimental Medical Science, Faculty of Medicine, </institution><institution>Lund University, </institution></institution-wrap>BMC C11, Sölvegatan 19, 221 84 Lund, Sweden </aff>
<aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0930 2361</institution-id><institution-id institution-id-type="GRID">grid.4514.4</institution-id><institution>Wallenberg Center for Molecular Medicine, </institution><institution>Lund University, </institution></institution-wrap>Lund, Sweden </aff>
<aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000000121839049</institution-id><institution-id institution-id-type="GRID">grid.5333.6</institution-id><institution>Animal Imaging and Technology Core (AIT), Center for Biomedical Imaging (CIBM), </institution><institution>Ecole Polytechnique Fédérale de Lausanne, </institution></institution-wrap>Lausanne, Switzerland </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>3</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>3</day>
<month>4</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<year>2019</year>
</pub-date>
<volume>44</volume>
<issue>1</issue>
<fpage>102</fpage>
<lpage>116</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>11</month>
<year>2017</year>
</date>
<date date-type="rev-recd">
<day>28</day>
<month>3</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>30</day>
<month>3</month>
<year>2018</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2018</copyright-statement>
<license license-type="OpenAccess">
<license-p><bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>In the past couple of decades, major efforts were made to increase reliability of metabolic assessments by magnetic resonance methods. Magnetic resonance spectroscopy (MRS) has been valuable for providing in vivo evidence and investigating biomarkers in neuropsychiatric disorders, namely schizophrenia. Alterations of glutamate and glutamine levels in brains of schizophrenia patients relative to healthy subjects are generally interpreted as markers of glutamatergic dysfunction. However, only a small fraction of MRS-detectable glutamate is involved in neurotransmission. Here we review and discuss brain metabolic processes that involve glutamate and that are likely to be implicated in neuropsychiatric disorders.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Glutamate</kwd>
<kwd>Glutamine</kwd>
<kwd>Schizophrenia</kwd>
<kwd>Metabolism</kwd>
<kwd>Magnetic resonance</kwd>
</kwd-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© Springer Science+Business Media, LLC, part of Springer Nature 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1" sec-type="introduction">
<title>Introduction</title>
<p>Schizophrenia is a heterogeneous neurodevelopmental disorder affecting multiple domains of brain function, resulting in positive symptoms (e.g. delusions, hallucinations), negative symptoms (e.g. apathy, emotional blunting, low motivation), and cognitive symptoms (e.g. deficits in memory, attention and problem solving), which typically develop in late adolescence or early adulthood. While many sites in the human genome show association with the risk of developing schizophrenia, this disorder results from a complex interaction of the genetic predisposition with environmental and epigenetic factors [<xref ref-type="bibr" rid="CR1">1</xref>].</p>
<p>A long-standing hypothesis of schizophrenia considers that dopamine depletion in the mesocortical neurons projecting from the ventral tegmentum to the prefrontal cortex results in feeble stimulation of neuronal dopamine D1 receptors, and contributes to negative symptoms and cognitive impairments. On the other hand, excessive activation of the mesolimbic pathway (projecting to the nucleus accumbens) results in overstimulation of D2 receptors, contributing to positive symptoms of schizophrenia. Antipsychotic treatments (e.g. haloperidol, clozapine) mainly target dopamine D2 receptors and effectively alleviate positive symptoms. However, negative symptoms and cognitive impairments are virtually irresponsive to typical antipsychotics because they involve other neurotransmission systems, namely those operated by glutamate and γ-aminobutyric acid (GABA), and are furthermore caused by a neurodegenerative process (discussed in [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]). Therefore, a hypothesis suggesting that <italic>N</italic>-methyl-<sc>d</sc>-aspartic acid (NMDA) receptor hypofunction and inadequate GABAergic transmission play a major role in the disease has emerged [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Normally, inhibitory interneurons monitor levels of excitatory neurotransmission via NMDA receptor signalling, and activated interneurons release GABA that acts on pyramidal neurons (glutamatergic) to achieve adequate excitatory–inhibitory balance. Due to NMDA receptor hypofunction, there is reduced NMDA receptor signalling in schizophrenia, which leads to a disruption of excitation monitoring, and thus GABAergic neurons respond as if excitatory transmission is insufficient. This poor negative feedback from GABAergic interneurons to pyramidal neurons results in increased glutamatergic neurotransmission that, in turn, leads to excitotoxicity. This hypothesis was supported by experiments on healthy humans that develop schizophrenia-like symptoms upon administration of ketamine at sub-anaesthetic doses [<xref ref-type="bibr" rid="CR5">5</xref>]. Nowadays, there are several lines of evidence that support the NMDA receptor hypothesis: (1) NMDA receptor blockade causes symptoms of schizophrenia; (2) neuropathological studies identified a schizophrenia-associated reduction of presynaptic markers for GABAergic interneurons in the hippocampus and the intermediate layers of the prefrontal and cingulate cortex, namely reduced expression and/or density of GABA transporters (GAT), glutamic acid decarboxylase GAD67 (but not GAD65), and the Ca<sup>2+</sup>-binding protein parvalbumine; (3) several genes implicated in schizophrenia are involved in regulating NMDA receptors [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p>
<p>Glutamatergic neurotransmission acts on dopaminergic neurons. Thus, excessive firing of disinhibited pyramidal neurons can eventually drive the increase in dopamine release that is responsible for the positive symptoms of schizophrenia. Indeed, NMDA receptor inhibition in the prefrontal cortex increases extracellular glutamate that acts on AMPA and kainate receptors, which in turn stimulate dopamine release in the prefrontal cortex and striatum ([<xref ref-type="bibr" rid="CR8">8</xref>] and references therein). Also in humans, sub-anaesthetic doses of ketamine stimulate striatal release of dopamine [<xref ref-type="bibr" rid="CR9">9</xref>]. Although NMDA receptor hypofunction in schizophrenia may be considered as a primary event leading to exacerbated dopaminergic transmission [<xref ref-type="bibr" rid="CR2">2</xref>–<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>], it remains unknown whether it is cause or consequence of GABAergic deficits.</p>
<p>Glutamatergic and GABAergic systems may be investigated in vivo using magnetic resonance (MR) methods. In particular, the concentrations of these neurotransmitters, as well as products of their metabolism (Fig. <xref ref-type="fig" rid="Fig1">1</xref>), are detectable by <sup>1</sup>H magnetic resonance spectroscopy (MRS) among several other metabolites that compose the so-called neurochemical profile [<xref ref-type="bibr" rid="CR10">10</xref>]. Notably, MRS has served to investigate metabolic impairments in a variety of neurodegenerative disorders [<xref ref-type="bibr" rid="CR11">11</xref>], and has also been employed to investigate biomarkers in psychiatric disorders, with strong incidence on schizophrenia [<xref ref-type="bibr" rid="CR12">12</xref>]. However, one notes a particular inconsistency in the reported neurochemical alterations from MRS studies on schizophrenia patients, which may be attributed to the intrinsic heterogeneity of the disorder.</p>
<p>
<fig id="Fig1"><label>Fig. 1</label><caption><p>Main pathways of glutamate metabolism in the brain. Glutamate, glutamine, GABA, <italic>N</italic>-acetylaspartate, NAAG, and glutathione are detectable by <sup>1</sup>H MRS</p></caption><graphic id="d29e433" xlink:href="11064_2018_2521_Fig1_HTML"></graphic></fig>
</p>
<p>In this work, we reviewed recent literature reporting MRS studies in the realm of schizophrenia. Rather than an extensive literature review, we focused on recent studies on schizophrenia patients and animal models that are relevant for supporting the glutamatergic dysfunction hypothesis. We further discuss the involvement of glutamatergic players on brain metabolism pathways.</p>
<sec id="Sec2">
<title>MRS in Schizophrenia</title>
<p>MRS allows the non-invasive measurement of stationary and dynamic information in humans and animals, i.e. concentrations of neurochemical compounds and metabolic fluxes, using MR-active nuclei such as <sup>1</sup>H, <sup>31</sup>P and <sup>13</sup>C. <sup>1</sup>H is the most sensitive nucleus for applications in living tissues and localized <sup>1</sup>H MRS provides the measurement of about 20 metabolites in the brain including those related to neurotransmission, namely glutamate (Glu), glutamine (Gln), GABA, aspartate (Asp), <italic>N</italic>-acetylaspartylglutamate (NAAG), glycine (Gly) and serine; energy metabolism, which includes phosphocreatine (PCr), creatine (Cr), glucose (Glc), lactate (Lac) and alanine (Ala); phospholipid precursors involved in membrane metabolism, particularly phosphorylcholine (PCho), glycerophosphorylcholine (GPC), phosphorylethanolamine (PE); the antioxidants glutathione (GSH) and ascorbate (Asc); major osmolytes namely <italic>myo</italic>-inositol (Ins; <italic>scyllo</italic>-inositol is often also quantified) and taurine (Tau); finally the putative neuronal marker <italic>N</italic>-acetylaspartate (NAA) that is a precursor of NAAG (Fig. <xref ref-type="fig" rid="Fig2">2</xref>a). <sup>31</sup>P MRS allows the measurement of energy related metabolites, namely ATP, phosphocreatine and inorganic phosphate (P<sub>i</sub>); membrane related phospholipid precursors including phosphomonoesters (PME): phosphocholine + phosphoethanolamine, reflecting membrane phospholipid synthesis, and phosphodiester (PDE): glycerophosphorylcholine + glycerophosphorylethanolamine, a marker of membrane degradation (Fig. <xref ref-type="fig" rid="Fig2">2</xref>b). Moreover, from the <sup>31</sup>P spectrum one can estimate the intra-/extra-cellular pH and free Mg<sup>2+</sup> concentration. <sup>13</sup>C MRS is a method with low sensitivity due to its low natural abundance and gyromagnetic ratio. However, in combination with the infusion of specific <sup>13</sup>C labelled substrates, it offers a unique way of measuring energy metabolic rates and neurotransmission in vivo [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Due to the technical complexity such as substrate infusions and radiofrequency power deposition, and the high cost of <sup>13</sup>C labelled compounds, its application in humans is limited as compared to animals. So far no <sup>13</sup>C MRS study in schizophrenia patients was reported.</p>
<p>
<fig id="Fig2"><label>Fig. 2</label><caption><p><bold>a</bold><sup>1</sup>H MR spectrum of the human medial prefrontal cortex acquired with the SPECIAL sequence at 3 T (TE/TR = 6/4000 ms, number of averages = 148) and the fits of individual metabolites including aspartate (Asp), phosphocreatine (PCr), creatine (Cr), γ-aminobutyric acid (GABA), glutamine (Gln), glutamate (Glu), phosphorylcholine (PCho), glycerophosphorylcholine (GPC), glutathione (GSH), glucose (Glc), lactate (Lac), glycine (Gly), <italic>myo</italic>-inositol (Ins), <italic>N</italic>-acetylaspartylglutamate (NAA), <italic>N</italic>-acetylaspartylglutamate (NAAG), phosphorylethanolamine (PE), <italic>scyllo</italic>-inositol (Scyllo), taurine (Tau) and macromolecules (MM). <bold>b</bold><sup>31</sup>P MR spectrum of the human occipital lobe at 7 T (a pulse-acquire sequence, spectral bandwidth = 6000 Hz, TR = 3 s, 320 averages, with baseline correction, no apodization). <italic>PCr</italic> phosphocreatine, <italic>ATP</italic> adenosine triphosphate, <italic>Pi</italic><sup><italic>int</italic></sup> intracellular inorganic phosphate, <italic>Pi</italic><sup><italic>ext</italic></sup> extracellular inorganic phosphate, <italic>PE</italic> phophothanolamine, <italic>PC</italic> phosphocoline, <italic>GPC</italic> glycerophosphocholine, <italic>GPE</italic> glycerophosphoethanolamine, <italic>NADH</italic> reduced form of nicotinamide adenine dinucleotide, <italic>NAD</italic><sup>+</sup> oxidized form of nicotinamide adenine dinucleotide, <italic>UPDG</italic> uridine diphosphoglucose</p></caption><graphic id="d29e583" xlink:href="11064_2018_2521_Fig2_HTML"></graphic></fig>
</p>
<sec id="Sec3">
<title><italic>N</italic>-Acetylaspartate</title>
<p><italic>N</italic>-Acetylaspartate is a putative marker of neuronal integrity, and is the most abundant metabolite in the central nervous system of adult mammals observed in <sup>1</sup>H MR spectra [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Therefore, its measurement in vivo by <sup>1</sup>H MRS is rather straightforward and observed results are more consistent in schizophrenia patients. Decrements of <italic>N</italic>-acetylaspartate levels were found across different brain regions of schizophrenia patients relative to healthy controls, namely in frontal lobe, hippocampus and thalamus [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. With the disease progression, the degree of reductions in <italic>N</italic>-acetylaspartate tends to accentuate in patients with chronic schizophrenia (versus first episode patients; [<xref ref-type="bibr" rid="CR17">17</xref>]). However, others have demonstrated increased <italic>N</italic>-acetylaspartate levels in hippocampus of chronic patients [<xref ref-type="bibr" rid="CR18">18</xref>] and prefrontal cortex of high-risk adolescents [<xref ref-type="bibr" rid="CR19">19</xref>]. Bustillo et al. reported recently that, with age, <italic>N</italic>-acetylaspartate increases in cortical grey matter and decreases in white matter of schizophrenia patients [<xref ref-type="bibr" rid="CR20">20</xref>]. A reduction of brain <italic>N</italic>-acetylaspartate concentration with age and disease duration was found in a meta-analysis by Brugger et al. [<xref ref-type="bibr" rid="CR21">21</xref>], and it is likely to reflect loss of neuronal metabolic integrity.</p>
</sec>
<sec id="Sec4">
<title>Glutamate and Glutamine</title>
<p>Alterations have also been abundantly reported for glutamine and glutamate, pointing towards schizophrenia-induced concentration changes in a time dependent manner: increased glutamine, glutamate and/or the ratio of glutamine-to-glutamate (Gln/Glu) have been found in early stages of the disease and unmedicated patients [<xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR27">27</xref>], whereas decreased levels of these amino acids have often been observed in chronic patients [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>–<xref ref-type="bibr" rid="CR31">31</xref>]. A recent meta-analysis suggested a decline with age and disease duration in the levels of glutamate and glutamine [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
<p>Note that <sup>1</sup>H MRS offers the measurement of neurochemical information at rest condition, while performing <sup>1</sup>H MRS measurement during a functional task so called functional MRS (fMRS) allows the unique measurement of dynamic information of glutamatergic and energy metabolism upon neuronal activation. In fMRS studies, glutamate increase is a common manifestation of neuronal activation that has been interpreted as a response to stimulated energy metabolism [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>] because brain net amino acid synthesis requires increased anaplerotic activity, namely through pyruvate carboxylation [<xref ref-type="bibr" rid="CR34">34</xref>]. These changes in glutamate levels are very subtle, and therefore such experiments require high sensitivity and stability of the MRS measurement. Recently, Taylor et al. conducted a fMRS study in schizophrenia patients at 7 T and, interestingly, they observed a delayed increase of glutamate levels in response to a cognitive task, comparing to healthy controls [<xref ref-type="bibr" rid="CR35">35</xref>]. This suggests a neurodegeneration-like effect involving glutamatergic neurotransmission and oxidative metabolism.</p>
</sec>
<sec id="Sec5">
<title>GABA</title>
<p>Converging evidence suggests that abnormal function of GABAergic parvalbumin-positive interneurons leading to a loss of the balance between neuronal excitation and inhibition, and to deficits in neuronal synchronization, may contribute to cognitive deficits in schizophrenia. Accordingly, a reduction of mRNA encoding for the GABA synthesis enzyme GAD67 and aberrant gamma waves [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>] were observed in schizophrenia patients [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. The measurement of excitatory neurotransmitter glutamate in vivo by <sup>1</sup>H MRS is straightforward due to its high cerebral concentration, on the contrary, the low level of GABA makes it challenging to be measured in vivo. Therefore, the number of studies of GABA by <sup>1</sup>H MRS is very limited and most studies were conducted by spectral editing methods at 3 T [<xref ref-type="bibr" rid="CR40">40</xref>–<xref ref-type="bibr" rid="CR46">46</xref>], at 4 T [<xref ref-type="bibr" rid="CR47">47</xref>], and recently also at 7 T [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR48">48</xref>, <xref ref-type="bibr" rid="CR49">49</xref>]. A comprehensive meta-analysis shows that no significant schizophrenia-associated changes in GABA levels can be identified in medial prefrontal cortex, parietal/occipital cortex and striatum, which is not consistent with the post-mortem studies indicating a reduction in GABA synthesis [<xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR39">39</xref>]. However, this may be attributed to the diverse methodologies used, the regional specificities or the compensation of other unaffected subtype of interneurons [<xref ref-type="bibr" rid="CR42">42</xref>].</p>
</sec>
<sec id="Sec6">
<title>Glutathione</title>
<p>Glutathione is a major cellular redox regulator and antioxidant protecting cell from damages induced by reactive oxygen species. Its levels are decreased in cerebrospinal fluid and medial prefrontal cortex of chronic schizophrenia patients [<xref ref-type="bibr" rid="CR50">50</xref>] and the lower glutathione levels are associated with more severe negative symptoms [<xref ref-type="bibr" rid="CR51">51</xref>]. Moreover, subjects carrying polymorphisms in the gene coding for the catalytic subunit of the glutamate–cysteine ligase (<italic>Gclc</italic>) that are associated with high risk of developing schizophrenia [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>] display lower glutathione concentrations in the medial prefrontal cortex than low-risk genotype subjects [<xref ref-type="bibr" rid="CR54">54</xref>]. Interestingly, low prefrontal glutamate levels are present in patients with low-risk genotypes [<xref ref-type="bibr" rid="CR54">54</xref>], suggesting a predominant pathogenic role of glutamatergic system impairments in <italic>Gclc</italic> low-risk genotypes. However, unchanged cerebral glutathione levels were also reported between patients and controls [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR55">55</xref>]. This may be linked to the different distributions of <italic>Gclc</italic> polymorphisms between groups and/or the measurement under resting conditions, where alterations may not be pronounced as under particular conditions, such as upon psychosocial stress exposure. However, stress-induced glutathione alterations remain to be directly demonstrated in patients or subjects at risk of developing schizophrenia. In addition, glutathione was also shown to associate with white matter integrity and resting-state functional connectivity along the cingulum bundle, and this association with functional connectivity seems to be disrupted in early psychosis patients [<xref ref-type="bibr" rid="CR56">56</xref>].</p>
</sec>
<sec id="Sec7">
<title>NAD<sup>+</sup>/NADH</title>
<p>The equilibrium between the oxidized (NAD<sup>+</sup>) and reduced (NADH) forms of nicotinamide adenine dinucleotide play a key role in many biological processes such as energy metabolism, antioxidation, and calcium homeostasis, and their ratio reflects cellular redox state. Their measurement in vivo is challenging due to its low concentration and limited spectral separation. With the increase of sensitivity and spectral dispersion at high magnetic fields, and with the improvements made for spectral fitting, recent studies have reported the measurement of NAD<sup>+</sup> and NADH in human brains in vivo by <sup>31</sup>P MRS [<xref ref-type="bibr" rid="CR57">57</xref>]. One application of this method revealed a significant reduction of redox state NAD<sup>+</sup>/NADH in both early psychosis and chronic patients, offering for the first time direct in vivo support of the presence of redox imbalance in schizophrenia patients, possibly linked to mitochondrial dysfunction and impaired energy metabolism [<xref ref-type="bibr" rid="CR58">58</xref>].</p>
</sec>
<sec id="Sec8">
<title>Mitochondrial Dysfunction</title>
<p>Abnormalities in mitochondrial function and energy metabolism have also been proposed to occur in patients with schizophrenia [<xref ref-type="bibr" rid="CR59">59</xref>]. Although as shown by <sup>31</sup>P MRS studies no consistent changes of ATP, phosphocreatine and P<sub>i</sub> can be identified from frontal lobe, temporal lobe and subcortical regions [<xref ref-type="bibr" rid="CR60">60</xref>], interestingly the reaction rate of creatine kinase, the enzyme catalysing the exchange between phosphocreatine and ATP, was decreased in anterior cingulate cortex of patients using magnetization transfer experiment in <sup>31</sup>P MRS [<xref ref-type="bibr" rid="CR61">61</xref>]. Apart from methodological heterogeneities (discussed in [<xref ref-type="bibr" rid="CR60">60</xref>]), the potential compensatory mechanism at rest likely plays a role such that dynamic change can be observed in the absence of changes in total resting pool size. In addition, accumulation of lactate was observed in medial prefrontal cortex [<xref ref-type="bibr" rid="CR62">62</xref>] and cerebral spinal fluid [<xref ref-type="bibr" rid="CR63">63</xref>] in schizophrenia patients, suggest a shift towards reliance on glycolysis for energy production, and may lead to lactic acidosis. Accordingly, low brain pH values in schizophrenia patients were observed in one <sup>31</sup>P MRS study [<xref ref-type="bibr" rid="CR61">61</xref>].</p>
<p>Taken together, the observations in patients by MRS studies indeed offer in vivo evidences supporting the presence of glutamatergic, redox and mitochondrial dysfunction in schizophrenia, despite many confounding factors involved such as MR methodologies, disease stage, region specificity, heterogeneity in patient cohorts and medication effects. It is important to note that compensatory mechanisms at resting state may mask changes in metabolite concentrations. In contrast, dynamic MRS measurements may be more informative, as is the case of fMRS studies [<xref ref-type="bibr" rid="CR35">35</xref>] and magnetization transfer experiments [<xref ref-type="bibr" rid="CR61">61</xref>] in patients.</p>
<p>Furthermore, one should note that only small fractions of the measured pools of glutamate and GABA are involved in neurotransmission. To directly address the aberrant glutamate and GABA neurotransmission, as well as energy metabolism pathways, future studies using <sup>13</sup>C MRS are required [<xref ref-type="bibr" rid="CR13">13</xref>] and are expected to provide novel insights in pathophysiology of schizophrenia.</p>
</sec>
</sec>
<sec id="Sec9">
<title>MRS on Animal Models: Glutamate/Glutamine Alterations</title>
<p>MRS can be applied in both clinical and pre-clinical settings, and thus represents a valuable method for translational research. The establishment of animal models for schizophrenia (and for the so complex psychiatric disorders in general) is challenging and does not fully recapitulate all behavioural phenotypes of the disease. Recent research on animal models has focused particularly on mice carrying modifications in genes associated to the risk of developing schizophrenia, as well as on the exposure to environmental insults. MRS has also been employed to identify metabolic modifications triggered by acute administration of NMDA receptor antagonists that mimic behavioural symptoms similar to those observed in schizophrenia (e.g. the open channel blockers phencyclidine, ketamine). In this section we assembled evidence from studies on animal models of schizophrenia and of psychological stress that triggers schizophrenia-like phenotypes, which might contribute to explain findings in the brain of schizophrenia patients.</p>
<p>Phencyclidine was reported to acutely induce a reduction of glutamate levels accompanied by glutamine accumulation (without changes in the total content of glutamate plus glutamine, called “Glx”) in the rat prefrontal cortex [<xref ref-type="bibr" rid="CR64">64</xref>]. This MRS study at high magnetic field supports changes in Gln/Glu as a putative marker for the glutamatergic dysfunction in schizophrenia. Psychosocial stress is a major trigger of neuropsychiatric disorders [<xref ref-type="bibr" rid="CR65">65</xref>–<xref ref-type="bibr" rid="CR67">67</xref>]. In rodents, exposure to stress early in life causes anxiety and depressive-like behaviours, and might also contribute to the development of schizophrenia-like behaviours [<xref ref-type="bibr" rid="CR68">68</xref>–<xref ref-type="bibr" rid="CR70">70</xref>]. Interestingly, Napolitano et al. reported that social isolation, an often used psychosocial stress paradigm, results in an altered response to a NMDA receptor non-competitive antagonist (ketamine) challenge in mice, namely an exacerbated ketamine-induced glutamine increase and a reduction of GABA concentration in the prefrontal cortex [<xref ref-type="bibr" rid="CR71">71</xref>]. In particular, exposing rodents to social isolation stress after weaning leads to mitochondrial dysfunction and increased oxidative stress [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR72">72</xref>], impaired function of oligodendrocytes that results in poor myelination [<xref ref-type="bibr" rid="CR73">73</xref>, <xref ref-type="bibr" rid="CR74">74</xref>], and degeneration of parvalbumine-positive neurons and neuroinflammation [<xref ref-type="bibr" rid="CR75">75</xref>] within the prefrontal cortex. These features are likely to cause alterations of the neurochemical profile measured by MRS. In a recent study, we observed that social isolation after weaning causes an increase of Gln/Glu, as well as a reduction of <italic>myo</italic>-inositol in the mouse frontal cortex [<xref ref-type="bibr" rid="CR76">76</xref>]. In addition, recent work suggests that a number of stress paradigms applied to mice early in life leads to reduced concentration of metabolites produced and stored in neurons, namely glutamate, GABA and <italic>N</italic>-acetylaspartate, almost exclusively in the prefrontal cortex ([<xref ref-type="bibr" rid="CR77">77</xref>] and references therein). Also Vernon et al. reported altered metabolite concentrations in the prefrontal cortex of adult mice born from females exposed to immune activation during gestation, namely decreased levels of glutathione, taurine and <italic>N</italic>-acetylaspartate [<xref ref-type="bibr" rid="CR78">78</xref>].</p>
<p>As discussed above, reduced levels of glutathione are a recurrent observation in the brains of schizophrenia patients, and genes involved in glutathione synthesis have been implicated in the disease [<xref ref-type="bibr" rid="CR79">79</xref>]. Mice with a functional deletion in the modulatory subunit of the glutamate–cysteine ligase (<italic>Gclm</italic>) display impaired glutathione synthesis leading to reduced glutathione levels in multiple organs, including the brain [<xref ref-type="bibr" rid="CR80">80</xref>, <xref ref-type="bibr" rid="CR81">81</xref>]. Compared to wild-type mice, <italic>Gclm</italic> −/− mice were reported to have delayed oligodendrocyte maturation (which depends on adequate intracellular redox balance) and myelination in the anterior cingulate cortex, and impaired white mater integrity [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Furthermore, early-life insults inducing oxidative stress in <italic>Gclm</italic> −/− mice are detrimental to immature parvalbumin-immunoreactive interneurons and have consequences for anterior cingulate cortex functioning in adulthood [<xref ref-type="bibr" rid="CR83">83</xref>]. Elevated Gln/Glu was also found in the frontal cortex of the <italic>Gclm</italic> −/− mouse relative to controls [<xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR84">84</xref>], which is further accentuated by social isolation stress after weaning [<xref ref-type="bibr" rid="CR76">76</xref>]. In line with these observations, glutamine synthetase was suggested to be impacted by oxidative stress [<xref ref-type="bibr" rid="CR85">85</xref>], which occurs in neuropsychiatric disorders and upon NMDA receptor inhibition [<xref ref-type="bibr" rid="CR78">78</xref>, <xref ref-type="bibr" rid="CR86">86</xref>]. Interestingly, a mouse model of schizophrenia induced by perinatal treatment with ketamine was reported to display a persistent reduction of glutathione and increased oxidative stress in the medial prefrontal cortex [<xref ref-type="bibr" rid="CR87">87</xref>], which was accompanied by impaired mitochondrial function, reduced parvalbumin expression, and disruption of the excitation–inhibition balance (reduced inhibition onto layer 2/3 pyramidal cells, and increased excitatory drive onto parvalbumin-positive interneurons). These alterations were ameliorated by <italic>N</italic>-acetylcysteine treatment [<xref ref-type="bibr" rid="CR87">87</xref>], a compound that might stimulate glutathione synthesis and also acts as antioxidant [<xref ref-type="bibr" rid="CR84">84</xref>, <xref ref-type="bibr" rid="CR87">87</xref>].</p>
</sec>
<sec id="Sec10">
<title>Cerebral Energy Metabolism and Glutamatergic Function</title>
<sec id="Sec11">
<title>Glutamatergic Neurotransmission and Signalling Through NMDA Receptors</title>
<p>Given its relatively large concentration in the brain (~ 10 mM in cortex), glutamate is of easy quantification by MRS [<xref ref-type="bibr" rid="CR10">10</xref>], and has been proposed as a biomarker for neurodegeneration in several pathologies [<xref ref-type="bibr" rid="CR11">11</xref>]. However, studies at low magnetic field are unable to distinguish between glutamate and glutamine signals and have reported the sum of their concentrations, called “Glx”.</p>
<p>Glutamate is the main excitatory neurotransmitter in the brain and plays a major role in psychopathology. Synaptic vesicles in nerve terminals of glutamatergic neurons are loaded with glutamate. Following an action potential, glutamate is released via exocytosis. Once in the synaptic cleft, it can activate ionotropic (ion channels) and metabotropic (GTP-binding protein coupled) receptors. The ligand-gated ion channels are further divided into three families: α-amino-3-hydroxy-5-methyl-isoxazole-4-propionate (AMPA), kainate and <italic>N</italic>-methyl-<sc>d</sc>-aspartate (NMDA). In the mammalian central nervous system, AMPA and kainate receptors mainly mediate rapid depolarizing responses, the excitatory post-synaptic currents (EPSCs) [<xref ref-type="bibr" rid="CR88">88</xref>]. The NMDA receptor participates mainly in synaptic plasticity and synapse formation, although it can also contribute to EPSPs and dendritic spikes [<xref ref-type="bibr" rid="CR89">89</xref>]. The family of metabotropic receptors comprises several members within three subtypes, all involved in modulating synaptic signalling by glutamate and other transmitters [<xref ref-type="bibr" rid="CR90">90</xref>].</p>
<p>As discussed above, NMDA receptors of the postsynaptic spine are of particular importance in the pathophysiology of schizophrenia. The NMDA receptor is a tetramer containing two subunits: NR1, which is required for channel function, and NR2A–D or NR3A,B, which determine biophysical and pharmacologic characteristics of the receptor (e.g. reviewed by [<xref ref-type="bibr" rid="CR3">3</xref>]). NMDA receptors require that two different ligands bind to open the ion channel: glutamate binds to a site on the NR2/3 subunit (same site of NMDA and aspartate binding), and glycine, <sc>d</sc>-serine, kynurenic acid or NAAG binds to the modulatory binding site on the NR1 subunit. The channel also comprises a binding site for dissociative anaesthetics, including phencyclidine, dizocilpine (MK-801) and ketamine. At resting membrane potential, the NMDA receptor channel is blocked by Mg<sup>2+</sup> that is released upon depolarization, allowing cation transport across the pore.</p>
<p>Glycine, Serine and NAAG are detectable in the brain by MRS, but their quantification may be hampered by the overlap with peaks from metabolites with much larger concentration, especially when operating at low magnetic fields [<xref ref-type="bibr" rid="CR10">10</xref>] where spectral resolution is poor. However, specific editing techniques have been employed to resolve signals of these metabolites in <sup>1</sup>H MRS [<xref ref-type="bibr" rid="CR91">91</xref>]. NAAG is of particular interest for glutamatergic neurotransmission. In addition to acting as an antagonist of the glycine site of the NMDA receptor [<xref ref-type="bibr" rid="CR92">92</xref>], NAAG is synthetized from glutamate (Fig. <xref ref-type="fig" rid="Fig1">1</xref>). It is a peptide widely spread in the nervous system and particularly concentrated in synaptic vesicles of presynaptic terminals, including those of pyramidal neurons in the cortex and limbic system, being co-released with glutamate [<xref ref-type="bibr" rid="CR93">93</xref>]. NAAG is synthetized from ATP-dependent condensation of <italic>N</italic>-acetylaspartate and glutamate in neurons (Fig. <xref ref-type="fig" rid="Fig1">1</xref>) catalysed by NAAG synthetase activities [<xref ref-type="bibr" rid="CR94">94</xref>, <xref ref-type="bibr" rid="CR95">95</xref>]. Although its role is not fully understood, NAAG does specifically interact with the NMDA receptor (but not with AMPA or kainate receptors) through which it modulates synaptic plasticity [<xref ref-type="bibr" rid="CR93">93</xref>]. Therefore, the balance between synaptic levels of glutamate and NAAG, as well as other ligands of the glycine site, is important to modulate cation translocation through the receptor’s pore.</p>
<p>Importantly, NAAG also acts on the metabotropic type II glutamate receptor mGluR3 [<xref ref-type="bibr" rid="CR96">96</xref>, <xref ref-type="bibr" rid="CR97">97</xref>] inhibiting the release of neurotransmitters, such as glutamate, GABA and glycine [<xref ref-type="bibr" rid="CR93">93</xref>, <xref ref-type="bibr" rid="CR96">96</xref>–<xref ref-type="bibr" rid="CR99">99</xref>]. Interestingly, it was reported that inhibitors of glutamate carboxypeptidase II (enzyme that inactivates <italic>N</italic>-acetylaspartylglutamate) are useful in rescuing memory impairments in rodent models of neurogenerative disorders [<xref ref-type="bibr" rid="CR100">100</xref>], as well as preventing increases in glutamate release induced by the NMDA receptor non-competitive antagonist phencyclidine, through NAAG actions on mGluR3 [<xref ref-type="bibr" rid="CR99">99</xref>]. Such evidence suggests that increasing levels of NAAG might help re-establishing the inhibitory–excitatory balance in schizophrenia.</p>
<p>Reduced cortical levels of NAAG have been reported in schizophrenia, as well as in bipolar disorder [<xref ref-type="bibr" rid="CR101">101</xref>]. A deficit in NAAG levels would therefore (1) increase the activity of NMDA receptors, leading to over-activation of GABAergic interneurons and consequently disinhibit pyramidal neurons, (2) and reduce the agonist action on mGluR3 receptors located pre-synaptically in glutamatergic neurons, thus removing the negative feedback. Both actions result in increased glutamate release.</p>
<p>Although brain NAAG occurs in concentrations detectable by MRS at high magnetic field, its main resonances overlap with those of <italic>N</italic>-acetylaspartate and are thus of difficult analysis [<xref ref-type="bibr" rid="CR10">10</xref>]. Therefore, the reduction of <italic>N</italic>-acetylaspartate levels reported in brains of schizophrenia patients (studies generally conducted at low magnetic field; see above) likely includes reduced NAAG.</p>
</sec>
<sec id="Sec12">
<title>Astrocytes are Capable of Regulating NMDA Receptor Activity</title>
<p>Glutamatergic signalling is terminated by an uptake mechanism that uses the driving force of Na<sup>+</sup>, K<sup>+</sup> and H<sup>+</sup> gradients to transport glutamate against its concentration gradient, keeping extracellular glutamate concentration below the level that activates its receptors (~ 1 µM; [<xref ref-type="bibr" rid="CR102">102</xref>, <xref ref-type="bibr" rid="CR103">103</xref>]). This transport mechanism not only ensures adequate synaptic signalling but also prevents glutamate-mediated excitotoxicity (excessive glutamatergic activity) that triggers brain injury. Astrocytes are crucial for glutamatergic neurotransmission, particularly by clearing glutamate of neuronal origin in their processes abutting synapses, by modulating neuronal activity, and by controlling nutrient delivery from circulation ([<xref ref-type="bibr" rid="CR34">34</xref>] and references therein).</p>
<p>Once glutamate is taken up by astrocytes, it can be either oxidised or converted to glutamine in an energy-dependent manner via the glial-specific enzyme, glutamine synthetase [<xref ref-type="bibr" rid="CR104">104</xref>]. Thus, the pool of astrocytic glutamate is considered much smaller than that of neurons, while the opposite is proposed for glutamine compartmentation (Fig. <xref ref-type="fig" rid="Fig3">3</xref>; discussed in [<xref ref-type="bibr" rid="CR105">105</xref>]). Glutamine, which is electrophysiologically inactive, is then shuttled to neurons, and the glutamate–glutamine cycle is finally completed by action of neuronal glutaminase and packing of the produced glutamate into vesicles. Therefore, it is generally considered that neurons include a large metabolic pool of glutamate separated from the pool that comprises vesicular glutamate. This is however an oversimplified view of metabolic compartmentation. It is important to note that both glutamate and glutamine can be diverted to a number of metabolic processes, such as the formation of GABA or glutathione, protein synthesis, or catabolism in the tricarboxylic acid (TCA) cycle (Fig. <xref ref-type="fig" rid="Fig1">1</xref>), which can result in multiple kinetically different glutamate pools. Also contributing to multiple pools is the intracellular tortuosity of diffusion paths that may render metabolic pools not fully interchangeable.</p>
<p>
<fig id="Fig3"><label>Fig. 3</label><caption><p>Relative sizes of the main cerebral pools of glutamate and glutamine linked to the TCA cycles of neurons and glial cells</p></caption><graphic id="d29e1163" xlink:href="11064_2018_2521_Fig3_HTML"></graphic></fig>
</p>
<p>The involvement of astrocytes in regulating NMDA activity is of importance for schizophrenia. First of all, as mentioned above, astrocytic processes that engulf glutamatergic synapses are equipped with high density of the transporters that clear synaptic glutamate, and readily respond to glutamate release by engaging paracrine signalling and stimulating its metabolism (reviewed by [<xref ref-type="bibr" rid="CR34">34</xref>]). Moreover, as expertly reviewed by others [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR93">93</xref>], astrocytes regulate the synaptic availability of NMDA receptor modulators: (1) kynurenic acid, an antagonist at the glycine binding site of the NMDA receptor, is produced from tryptophan and released by astrocytes; (2) astrocytes possess the glycine transporter type 1 that regulates synaptic levels of glycine; (3) both serine racemase that synthesizes <sc>d</sc>-serine, and <sc>d</sc>-amino acid oxidase that catabolizes <sc>d</sc>-serine are localized in astrocytes; (4) astrocytic end-feet contain glutamate carboxypeptidase II that catabolises NAAG to <italic>N</italic>-acetylaspartate and glutamate. Malfunctioning of any of these pathways in astrocytes is likely causing schizophrenia-like phenotypes. Nevertheless, the major role of astrocytes in regulating glutamatergic activity remains the clearance of synaptic glutamate and maintenance of the glutamate–glutamine cycle, which are energetically costly [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR102">102</xref>].</p>
<p>Many studies found reduced levels of glutamate transporters in the brain of schizophrenia patients, which could contribute to glutamate accumulation after release into the synapse (e.g. [<xref ref-type="bibr" rid="CR106">106</xref>, <xref ref-type="bibr" rid="CR107">107</xref>]; reviewed in [<xref ref-type="bibr" rid="CR108">108</xref>]). A recent study analysed cell-specific expression of transporters, and reported that the density of glutamate transporters is reduced in astrocytes but not in neurons [<xref ref-type="bibr" rid="CR109">109</xref>]. This suggests that the astrocytic support to glutamatergic neurotransmission is impaired. In addition, differential mRNA expression of splice variants of the excitatory amino acid transporters EAAT1 and EAAT2 was observed in pyramidal neurons of the anterior cingulate cortex in the schizophrenia post-mortem brain [<xref ref-type="bibr" rid="CR110">110</xref>]. Also polymorphisms of EAAT1 and EAAT2 were proposed to be associated with cognitive performance in schizophrenia [<xref ref-type="bibr" rid="CR111">111</xref>]. These findings provide an additional dimension to the regulation of glutamate transport that is relevant for schizophrenia but remains to be understood.</p>
<p>Another point of glutamatergic regulation by astrocytes is the glutamate dehydrogenase, a mitochondrial enzyme that catabolises glutamate to 2-oxoglutarate for mitochondrial further oxidation (see [<xref ref-type="bibr" rid="CR34">34</xref>] and references therein). Reduced glutamate dehydrogenase activity and concomitant increased hippocampal glutamate levels were found in patients with mesial temporal lobe epilepsy, with SCZ-like psychotic symptoms and cognitive deficits [<xref ref-type="bibr" rid="CR112">112</xref>]. However, inconsistent findings on glutamate dehydrogenase have reported in post-mortem analyses of brains from schizophrenia patients [<xref ref-type="bibr" rid="CR113">113</xref>–<xref ref-type="bibr" rid="CR115">115</xref>]. Interestingly, a brain-specific glutamate dehydrogenase knock-out mouse was reported to show schizophrenia-like behaviours, reduced hippocampal volume, disrupted hippocampal excitatory–inhibitory balance [<xref ref-type="bibr" rid="CR115">115</xref>].</p>
<p>Both glutamate uptake by astrocytes and its mitochondrial catabolism initiated by glutamate dehydrogenase are important nodes of glutamatergic regulation within astrocytes, and alterations of these processes might contribute to metabolic deregulation in schizophrenia.</p>
</sec>
<sec id="Sec13">
<title>Energy Metabolism and the Glutamate–Glutamine Cycle</title>
<p>Brain function is demanding in terms of energetic requirements, as all transport of ions across cell membranes is dependent on ATP, the main cellular energy carrier. When ion translocation does not require direct ATP hydrolysis, this takes place upon subsequent reestablishment of the ionic gradients. Thus, glutamatergic dysfunction in schizophrenia is certainly associated to metabolic impairments.</p>
<p>Most of the cell’s ATP is produced by oxidative phosphorylation using reducing equivalents generated by the TCA cycle in the mitochondria. Therefore, both neurons and astrocytes stimulate their TCA cycle rates in response to increased activity, namely glutamatergic neurotransmission [<xref ref-type="bibr" rid="CR105">105</xref>].</p>
<p>As discussed elsewhere [<xref ref-type="bibr" rid="CR10">10</xref>], the pool of glutamate involved in synaptic transmission is much smaller than that associated to energy metabolism (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). Thus, it is likely that alterations of energy metabolism in schizophrenia represent a major contribution to changes in the levels of cerebral glutamate and glutamine (as well as <italic>N</italic>-acetylaspartate that is produced in mitochondria; [<xref ref-type="bibr" rid="CR15">15</xref>]) measured by MRS in patients relative to healthy subjects. Accordingly, in a study of the aging human brain, Boumezbeur and co-authors employed <sup>1</sup>H and <sup>13</sup>C MRS, and identified a correlation between levels of glutamate and <italic>N</italic>-acetylaspartate (taken as marker of neuronal integrity) and the TCA cycle rate in neurons, as well as between the levels of <italic>myo</italic>-inositol (a putative glial marker, discussed in [<xref ref-type="bibr" rid="CR10">10</xref>]) and the TCA cycle rate in glial cells [<xref ref-type="bibr" rid="CR116">116</xref>].</p>
<p>There is indeed abundant evidence pointing towards metabolic dysfunction in schizophrenia. Many studies found altered expression of genes related to brain energy metabolism in schizophrenia patients [<xref ref-type="bibr" rid="CR117">117</xref>, <xref ref-type="bibr" rid="CR118">118</xref>]. In an interesting study that combined transcriptomics, proteomics and metabolomics on the prefrontal cortex of schizophrenia patients and controls (post-mortem), nearly half the altered proteins were associated with mitochondrial function, metabolism and oxidative stress, and were indeed associated with alterations at transcriptional and metabolic levels [<xref ref-type="bibr" rid="CR119">119</xref>]. Regarding oxidative metabolism, several studies reported that schizophrenia alters the expression and activity of enzymes of the TCA cycle, as well as components of the mitochondrial electron transport chain and oxidative phosphorylation [<xref ref-type="bibr" rid="CR120">120</xref>]. Compared to controls, reduced number and size of mitochondria have also been reported in neurons and oligodendrocytes of brains of schizophrenia patients (e.g. [<xref ref-type="bibr" rid="CR121">121</xref>, <xref ref-type="bibr" rid="CR122">122</xref>]). In addition, impaired cerebral metabolic rate of glucose in schizophrenia patients was observed in positron emission tomography studies, namely in frontal areas [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>]. Studies of functional magnetic resonance imaging further suggest an impairment of cerebral blood flow and/or oxygen metabolism, consistent with a disruption of the neurovascular and/or neurometabolic coupling in frontal areas of patients with schizophrenia both at rest and during activation [<xref ref-type="bibr" rid="CR125">125</xref>, <xref ref-type="bibr" rid="CR126">126</xref>].</p>
<p>Research in animal models confirmed such brain metabolic disturbances. Acute antagonism of NMDA receptors modulates mitochondrial oxidative metabolism, as was for example demonstrated in the rat (e.g. [<xref ref-type="bibr" rid="CR127">127</xref>]). Mimicking persistent hypofunction of NMDA receptors, a sub-anaesthetic dose of ketamine administered to rats over a week resulted in impaired activities of mitochondrial respiratory chain complexes in the prefrontal cortex, striatum and hippocampus [<xref ref-type="bibr" rid="CR128">128</xref>]. Rodents exposed to social isolation stress after weaning, which is recognised to contribute for developing anxiety, and depressive- and schizophrenia-like behaviours [<xref ref-type="bibr" rid="CR68">68</xref>], also display mitochondrial dysfunction and increased oxidative stress in cortical areas [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR72">72</xref>, <xref ref-type="bibr" rid="CR129">129</xref>].</p>
<p>However, such impairments in components of mitochondrial metabolism may not directly translate to alterations of metabolic fluxes in vivo due to potential compensatory mechanisms. As discussed above, glutamate release is tightly coupled to energy metabolism. According to the glutamatergic hypothesis of schizophrenia, reduction of NMDA receptor activity in inhibitory neurons results in disinhibition of pyramidal cells with concomitant stimulation of glutamate release, and an increase in oxidative metabolism is thus expected. Indeed, increased extracellular glutamate after systemic injections of NMDA receptor antagonists, such as the open channel blockers phencyclidine and ketamine, was observed using micro-dialysis in the prefrontal cortex [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR130">130</xref>].</p>
<p>This released glutamate is likely taken by astrocytes and accumulated in the form of glutamine, which can be provided to neurons, and a glutamate–glutamine cycle rate increase is expected to result in stimulation of neuronal and astrocytic TCA cycle [<xref ref-type="bibr" rid="CR105">105</xref>, <xref ref-type="bibr" rid="CR131">131</xref>]. Accordingly, a phencyclidine-induced glutamate reduction and glutamine increase were reported by Iltis et al. [<xref ref-type="bibr" rid="CR64">64</xref>]. In a later study, Chowdhury et al. employed <sup>1</sup>H-[<sup>13</sup>C] MRS to measure rates of global energy metabolism and the glutamate–glutamine cycle in the frontal cortex and hippocampus of rats acutely treated with ketamine. Indeed, a sub-anaesthetic, but not anaesthetic, dose of ketamine significantly increased the fraction of <sup>13</sup>C labelling in carbons of glutamate, GABA and glutamine upon infusion of either [1-<sup>13</sup>C]glucose or the glial specific substrate [2-<sup>13</sup>C]acetate [<xref ref-type="bibr" rid="CR132">132</xref>]. Altogether, these observations suggest that NMDA receptor antagonists (administered at a sub-anaesthetic dose) result in stimulation of the glutamate–glutamine cycle rate as well as of oxidative metabolism in both neurons and astrocytes within the prefrontal cortex.</p>
<p>It should be noted, however, that not all cortical areas are likely to present the same metabolic alterations in schizophrenia, as is evidenced for example in positron emission tomography studies [<xref ref-type="bibr" rid="CR123">123</xref>, <xref ref-type="bibr" rid="CR124">124</xref>, <xref ref-type="bibr" rid="CR133">133</xref>]. In these lines, a recent study in a methylazoxymethanol acetate rat model of schizophrenia showed that resting oxidative metabolism, as measured by <sup>1</sup>H-[<sup>13</sup>C] MRS with administration of [1,6-<sup>13</sup>C]glucose, was reduced in the orbitofrontal cortex, increased in the visual cortex, and unaltered in the somatosensory cortex and dorsal hippocampus, when compared to controls [<xref ref-type="bibr" rid="CR134">134</xref>]. These observations were compatible with functional and structural connectivity differences and behavioural outcomes, which indicated hypofrontality and posterior hyperactivity [<xref ref-type="bibr" rid="CR134">134</xref>].</p>
<p>Changes of energy metabolism require a direct match of glucose utilisation rates. Upon phencyclidine administration, Iltis and co-workers observed an immediate rise in cortical glucose levels that normalised within 30 min, while lactate content was substantially reduced and took nearly 1 h to reach baseline levels [<xref ref-type="bibr" rid="CR64">64</xref>]. These observations are compatible with an initial reduction of glycolysis upon acute phencyclidine administration. Accordingly, glucose utilisation was found decreased within some cortical areas after 2 min of phencyclidine administration [<xref ref-type="bibr" rid="CR135">135</xref>]. Notably, 1–3 h after administration of NMDA receptor antagonists, increased glucose utilisation was shown in the prefrontal cortex, as well as in other cortical areas (mainly layers 1–3) and in parts of the limbic system [<xref ref-type="bibr" rid="CR135">135</xref>, <xref ref-type="bibr" rid="CR136">136</xref>], which is consistent with increased metabolism in neurons and astrocytes [<xref ref-type="bibr" rid="CR132">132</xref>]. Also in humans, NMDA receptor blockade with sub-anaesthetic doses of ketamine enhances blood flow and glucose utilisation in the prefrontal cortex and anterior cingulate cortex [<xref ref-type="bibr" rid="CR137">137</xref>–<xref ref-type="bibr" rid="CR139">139</xref>].</p>
<p>Investigation of brain energy metabolism in schizophrenia patients has been attempted. In particular, as noted above, <sup>31</sup>P MRS has been used to measure the content of phosphorus-containing compounds in the brain of schizophrenia patients, including ATP and phosphocreatine that are related to energy metabolism [<xref ref-type="bibr" rid="CR60">60</xref>]. Although few <sup>31</sup>P MRS studies showed reduced levels of these energy-related metabolites in cortical areas of patients relative to healthy subjects, a comprehensive review of the available literature led Yuksel and co-authors to observe that available data is highly variable and there are inconclusive in terms of metabolic alterations. First, <sup>31</sup>P MRS studies typically have small sample sizes, which masks potential schizophrenia-induced alterations. Another major concern is the lack of control on the medication effects and illness progression. Finally, it is clear that methodological improvements are required for standardisation of the acquired data: studies should be conducted at high magnetic field strengths to increase sensitivity and spectral resolution; and there should be a correction for the tissue composition (white matter, grey matter, cerebral spinal fluid) of the volume-of-interest used for signal detection because it is known to change with disease progression.</p>
<p>It is likely that brain homeostasis is maintained, thus resulting in unaltered baseline metabolite concentrations, whereas the response to a stress challenge of a complex, energetically demanding task may reveal specific metabolic impairments (discussed in [<xref ref-type="bibr" rid="CR77">77</xref>]). In a recent study on bipolar disorder patients, <sup>31</sup>P MRS was performed in the visual cortex during a visual stimulation task [<xref ref-type="bibr" rid="CR140">140</xref>]. While there were no ATP or phosphocreatine abnormalities at baseline, there were distinct stimulation-induced metabolic changes in patients and healthy controls: visual stimulation reduced the levels of phosphocreatine but not ATP in controls, and reduced the levels of ATP but not phosphocreatine in patients. These results suggest that the visual cortex of bipolar disorder patients is limited in recruiting phosphocreatine as energetic buffer through creatine kinase.</p>
<p>The rate of creatine kinase can be directly measured in vivo using magnetisation transfer technics combined with <sup>31</sup>P MRS. In the frontal cortex of schizophrenia patients, Du et al. [<xref ref-type="bibr" rid="CR61">61</xref>] reported a significant reduction of the creatine kinase reaction rate, while phosphocreatine and ATP levels were normal at baseline.</p>
<p>Interestingly, reduced glucose tolerance and impaired insulin sensitivity have been reported in schizophrenia patients and their siblings, relative to healthy subjects [<xref ref-type="bibr" rid="CR141">141</xref>–<xref ref-type="bibr" rid="CR143">143</xref>], which suggests that metabolic dysfunction in schizophrenia is not exclusive to the brain. It should be noted as well that impaired metabolism and mitochondrial dysfunction were also suggested to occur in other psychiatric disorders such as bipolar disorder [<xref ref-type="bibr" rid="CR144">144</xref>, <xref ref-type="bibr" rid="CR145">145</xref>], major depressive disorder [<xref ref-type="bibr" rid="CR146">146</xref>] or autism [<xref ref-type="bibr" rid="CR147">147</xref>].</p>
<p>Metabolic impairments linked to mitochondrial dysfunction are accompanied by oxidative stress, which is an important component of schizophrenia. As reviewed elsewhere [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR86">86</xref>], impairments in redox homeostasis and susceptibility of increased oxidative stress are linked to glutamatergic dysfunction due to (1) hypoactive NMDA receptors, (2) to degeneration of fast-spiking parvalbumin-positive GABAergic interneurons that are essential for fast local neuronal synchronization, (3) to dysfunctional oligodendrocytes resulting in poor myelination and thus impairing axonal integrity and signal conduction across brain areas, and (4) to neuroinflammation.</p>
</sec>
<sec id="Sec14">
<title>Glutamate as a Marker for Neuronal Density</title>
<p>Glutamate is the most concentrated amino acid in the brain. As discussed above, glutamine synthetase resides exclusively in glial cells, and neurons readily convert glutamine into glutamate (Fig. <xref ref-type="fig" rid="Fig3">3</xref>). Thus, while most glutamate resides in neurons of the mammalian brain, glutamine is thought to be mainly localized to astrocytes (for revision see [<xref ref-type="bibr" rid="CR34">34</xref>]). Therefore, a reduction in the size or amount of space occupied by neurons, relative to the volume occupied by other brain cells, might result in a reduction of glutamate concentration relative to that of glutamine.</p>
<p>In the <italic>Gclm</italic> −/− mouse model of schizophrenia, we found increased Gln/Glu in the frontal cortex (relative to both +/+ and +/− mice), without a reduction of glutamate but an increase in glutamine levels [<xref ref-type="bibr" rid="CR76">76</xref>, <xref ref-type="bibr" rid="CR82">82</xref>, <xref ref-type="bibr" rid="CR84">84</xref>]. Moreover, social isolation in mice was also found to cause an increase in the ratio of glutamine-to-glutamate (Gln/Glu) in the frontal cortex and a trend towards a decrease in glutamate concentration [<xref ref-type="bibr" rid="CR76">76</xref>]. Since glutamate is primarily located in neurons, neuronal loss or reduced neuronal processes are likely to result in decreased tissue glutamate content [<xref ref-type="bibr" rid="CR10">10</xref>]. Supporting this notion, chronic stress was reported to result in a marked reduction of the dendritic arborisation in the medial prefrontal cortex [<xref ref-type="bibr" rid="CR148">148</xref>–<xref ref-type="bibr" rid="CR150">150</xref>]. Chronic social isolation stress was also shown to reduce levels of glutamate receptors in cortical areas and the hippocampal formation [<xref ref-type="bibr" rid="CR151">151</xref>–<xref ref-type="bibr" rid="CR153">153</xref>], suggesting impairments in glutamatergic neurons.</p>
<p>Increased Gln/Glu was also reported in the cerebrospinal fluid of schizophrenia patients, relative to healthy subjects [<xref ref-type="bibr" rid="CR23">23</xref>]. Bustillo et al. reported higher anterior cingulate Gln/Glu in minimally treated patients than in control subjects [<xref ref-type="bibr" rid="CR24">24</xref>]. Interestingly, glutamate was reported to be higher in young schizophrenia patients, but to decrease with age, relative to healthy subjects [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR26">26</xref>].</p>
<p>Neurons are also the primary reservoir of <italic>N</italic>-acetylaspartate. The concentration of <italic>N</italic>-acetylaspartate is relatively high in neurons and, since it is synthetized in neuronal mitochondria and endoplasmic reticulum [<xref ref-type="bibr" rid="CR15">15</xref>], it is sensitive to mitochondrial dysfunction and deleterious effects of oxidative stress, being considered a marker of neuronal health (reviewed in [<xref ref-type="bibr" rid="CR10">10</xref>]). Interestingly, since <italic>N</italic>-acetylaspartate hydrolysis by aspartylacylase in oligodendrocytes and astrocytes produces oxaloacetate and acetate that are substrates for the TCA cycle, it can serve either for fuelling activity of these glial cells or for de novo glutamate synthesis [<xref ref-type="bibr" rid="CR154">154</xref>]. Impairments of aspartylacylase activity are thus likely to result in increased <italic>N</italic>-acetylaspartate levels without improved mitochondrial function in neurons (e.g. [<xref ref-type="bibr" rid="CR155">155</xref>]).</p>
<p>Correlation between concentrations of <italic>N</italic>-acetylaspartate and glutamate is observable in the brains of both rodents [<xref ref-type="bibr" rid="CR156">156</xref>] and humans [<xref ref-type="bibr" rid="CR157">157</xref>]. This correlation between the neuronal markers <italic>N</italic>-acetylaspartate and glutamate has been found disrupted in frontal areas of patients with neuropsychiatric disorders, including schizophrenia (e.g. [<xref ref-type="bibr" rid="CR158">158</xref>, <xref ref-type="bibr" rid="CR159">159</xref>]). Importantly, in schizophrenia, glutamate loss was found to correlate with functional deterioration and with grey matter loss [<xref ref-type="bibr" rid="CR160">160</xref>]. This is consistent with glutamate being a marker for neurodegeneration.</p>
</sec>
</sec>
</sec>
<sec id="Sec15" sec-type="conclusion">
<title>Conclusion</title>
<p>Although changes in glutamate levels in schizophrenia have been linked to impaired glutamatergic neurotransmission and hypofunction of NMDA receptors, it is likely that glutamate alterations also result from metabolic impairments, particularly at mitochondrial level. Moreover, given the primary location of glutamate in neurons and glutamine in astrocytes, one must consider that deterioration of neuronal processes, reduction of dendritic arborisations, etc. might result in increased Gln/Glu.</p>
</sec>
</body>
<back>
<glossary>
<title>Abbreviations</title>
<def-list>
<def-item>
<term>AMPA</term>
<def>
<p>α-Amino-3-hydroxy-5-methyl-isoxazole-4-propionate</p>
</def>
</def-item>
<def-item>
<term>ATP</term>
<def>
<p>Adenosine triphosphate</p>
</def>
</def-item>
<def-item>
<term>EPSCs</term>
<def>
<p>Excitatory post-synaptic currents</p>
</def>
</def-item>
<def-item>
<term>GABA</term>
<def>
<p>γ-Aminobutyric acid</p>
</def>
</def-item>
<def-item>
<term>Glx</term>
<def>
<p>Glutamate plus glutamine</p>
</def>
</def-item>
<def-item>
<term>mGluR2/3</term>
<def>
<p>Metabotropic glutamate receptors 2 or 3</p>
</def>
</def-item>
<def-item>
<term>MR</term>
<def>
<p>Magnetic resonance</p>
</def>
</def-item>
<def-item>
<term>MRS</term>
<def>
<p>Magnetic resonance spectroscopy</p>
</def>
</def-item>
<def-item>
<term>NAAG</term>
<def>
<p><italic>N</italic>-Acetylaspartylglutamate</p>
</def>
</def-item>
<def-item>
<term>NMDA</term>
<def>
<p><italic>N</italic>-Methyl-<sc>d</sc>-aspartate</p>
</def>
</def-item>
<def-item>
<term>TCA</term>
<def>
<p>Tricarboxylic acid</p>
</def>
</def-item>
</def-list>
</glossary>
<ack>
<title>Acknowledgements</title>
<p>J. Duarte is generously supported by the Knut and Alice Wallenberg Foundation. L. Xin is supported by the Centre d’Imagerie BioMédicale (CIBM) of the UNIL, UNIGE, HUG, CHUV, EPFL and the Leenaards and Jeantet Foundations.</p>
</ack>
<notes>
<title>Compliance with Ethical Standards</title>
<notes notes-type="COI-statement">
<title>Conflict of interest</title>
<p>None of the authors have conflicts of interest to declare.</p>
</notes>
</notes>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cariaga-Martinez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Saiz-Ruiz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alelú-Paz</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>From linkage studies to epigenetics: what we know and what we need to know in the neurobiology of schizophrenia</article-title>
<source/>Front Neurosci
          <year>2016</year>
<volume>10</volume>
<fpage>202</fpage>
<pub-id pub-id-type="pmid">27242407</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coyle</surname>
<given-names>JT</given-names>
</name>
</person-group>
<article-title>Glutamate and schizophrenia: beyond the dopamine hypothesis</article-title>
<source/>Cell Mol Neurobiol
          <year>2006</year>
<volume>26</volume>
<issue>4–6</issue>
<fpage>365</fpage>
<lpage>384</lpage>
<pub-id pub-id-type="pmid">16773445</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Tsien</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Goff</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Halassa</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia</article-title>
<source/>Schizophr Res
          <year>2015</year>
<volume>167</volume>
<issue>1–3</issue>
<fpage>98</fpage>
<lpage>107</lpage>
<pub-id pub-id-type="pmid">25583246</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lisman</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Green</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Javitt</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Benes</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Heckers</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Grace</surname>
<given-names>AA</given-names>
</name>
</person-group>
<article-title>Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia</article-title>
<source/>Trends Neurosci
          <year>2008</year>
<volume>31</volume>
<issue>5</issue>
<fpage>234</fpage>
<lpage>242</lpage>
<pub-id pub-id-type="pmid">18395805</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krystal</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Karper</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Seibyl</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Delaney</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bremner</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Heninger</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Bowers</surname>
<given-names>MB</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Charney</surname>
<given-names>DS</given-names>
</name>
</person-group>
<article-title>Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses</article-title>
<source/>Arch Gen Psychiatry
          <year>1994</year>
<volume>51</volume>
<issue>3</issue>
<fpage>199</fpage>
<lpage>214</lpage>
<pub-id pub-id-type="pmid">8122957</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carlsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Waters</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Holm-Waters</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tedroff</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carlsson</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence</article-title>
<source/>Annu Rev Pharmacol Toxicol
          <year>2001</year>
<volume>41</volume>
<fpage>237</fpage>
<lpage>260</lpage>
<pub-id pub-id-type="pmid">11264457</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coyle</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Goff</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia</article-title>
<source/>Ann NY Acad Sci
          <year>2003</year>
<volume>1003</volume>
<fpage>318</fpage>
<lpage>327</lpage>
<pub-id pub-id-type="pmid">14684455</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moghaddam</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Daly</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex</article-title>
<source/>J Neurosci
          <year>1997</year>
<volume>17</volume>
<issue>8</issue>
<fpage>2921</fpage>
<lpage>2927</lpage>
<pub-id pub-id-type="pmid">9092613</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kegeles</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Abi-Dargham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zea-Ponce</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Rodenhiser-Hill</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Van Heertum</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>TB</given-names>
</name>
<name>
<surname>Carlsson</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Laruelle</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia</article-title>
<source/>Biol Psychiatry
          <year>2000</year>
<volume>48</volume>
<issue>7</issue>
<fpage>627</fpage>
<lpage>640</lpage>
<pub-id pub-id-type="pmid">11032974</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mlynárik</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>The neurochemical profile quantified by in vivo <sup>1</sup>H NMR spectroscopy</article-title>
<source/>NeuroImage
          <year>2012</year>
<volume>61</volume>
<issue>2</issue>
<fpage>342</fpage>
<lpage>362</lpage>
<pub-id pub-id-type="pmid">22227137</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
<name>
<surname>Schuck</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Wenk</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>GC</given-names>
</name>
</person-group>
<article-title>Metabolic disturbances in diseases with neurological involvement</article-title>
<source/>Aging Dis
          <year>2014</year>
<volume>5</volume>
<issue>4</issue>
<fpage>238</fpage>
<lpage>255</lpage>
<pub-id pub-id-type="pmid">25110608</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Port</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Agarwal</surname>
<given-names>N</given-names>
</name>
</person-group>
<article-title>MR spectroscopy in schizophrenia</article-title>
<source/>J Magn Reson Imaging
          <year>2011</year>
<volume>34</volume>
<issue>6</issue>
<fpage>1251</fpage>
<lpage>1261</lpage>
<pub-id pub-id-type="pmid">22102558</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Adriany</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>IY</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Lei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Oz</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Localized in vivo <sup>13</sup>C NMR spectroscopy of the brain</article-title>
<source/>NMR Biomed
          <year>2003</year>
<volume>16</volume>
<issue>6–7</issue>
<fpage>313</fpage>
<lpage>338</lpage>
<pub-id pub-id-type="pmid">14679498</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lanz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
</person-group>
<article-title>Metabolic flux and compartmentation analysis in the brain in vivo</article-title>
<source/>Front Endocrinol
          <year>2013</year>
<volume>4</volume>
<fpage>156</fpage>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moffett</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Arun</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Madhavarao</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Namboodiri</surname>
<given-names>AM</given-names>
</name>
</person-group>
<article-title><italic>N</italic>-Acetylaspartate in the CNS: from neurodiagnostics to neurobiology</article-title>
<source/>Prog Neurobiol
          <year>2007</year>
<volume>81</volume>
<issue>2</issue>
<fpage>89</fpage>
<lpage>131</lpage>
<pub-id pub-id-type="pmid">17275978</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steen</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Hamer</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Measurements of brain metabolites by <sup>1</sup>H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis</article-title>
<source/>Neuropsychology
          <year>2005</year>
<volume>30</volume>
<issue>11</issue>
<fpage>1949</fpage>
<lpage>1962</lpage>
</element-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwerk</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Alves</surname>
<given-names>FD</given-names>
</name>
<name>
<surname>Pouwels</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>van Amelsvoort</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Metabolic alterations associated with schizophrenia: a critical evaluation of proton magnetic resonance spectroscopy studies</article-title>
<source/>J Neurochem
          <year>2014</year>
<volume>128</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>87</lpage>
<pub-id pub-id-type="pmid">23937509</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lutkenhoff</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>van Erp</surname>
<given-names>TG</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Therman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Manninen</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huttunen</surname>
<given-names>MO</given-names>
</name>
<name>
<surname>Kaprio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lönnqvist</surname>
<given-names>J</given-names>
</name>
<name>
<surname>O’Neill</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cannon</surname>
<given-names>TD</given-names>
</name>
</person-group>
<article-title>Proton MRS in twin pairs discordant for schizophrenia</article-title>
<source/>Mol Psychiatry
          <year>2010</year>
<volume>15</volume>
<issue>3</issue>
<fpage>308</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="pmid">18645571</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Keshavan</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Dick</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Diwadkar</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Montrose</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Prasad</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Stanley</surname>
<given-names>JA</given-names>
</name>
</person-group>
<article-title>Striatal metabolic alterations in non-psychotic adolescent offspring at risk for schizophrenia: a <sup>1</sup>H spectroscopy study</article-title>
<source/>Schizophr Res
          <year>2009</year>
<volume>115</volume>
<fpage>88</fpage>
<lpage>93</lpage>
<pub-id pub-id-type="pmid">19748228</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bustillo</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Lemke</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Abbott</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Qualls</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Stromberg</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Canive</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gasparovic</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Glutamatergic and neuronal dysfunction in gray and white matter: a spectroscopic imaging study in a large schizophrenia sample</article-title>
<source/>Schizophr Bull
          <year>2017</year>
<volume>43</volume>
<issue>3</issue>
<fpage>611</fpage>
<lpage>619</lpage>
<pub-id pub-id-type="pmid">27550776</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brugger</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Leucht</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stone</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Proton magnetic resonance spectroscopy and illness stage in schizophrenia: a systematic review and meta-analysis</article-title>
<source/>Biol Psychiatry
          <year>2011</year>
<volume>69</volume>
<issue>5</issue>
<fpage>495</fpage>
<lpage>503</lpage>
<pub-id pub-id-type="pmid">21145039</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tibbo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hanstock</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Valiakalayil</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Allen</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia</article-title>
<source/>Am J Psychiatry
          <year>2004</year>
<volume>161</volume>
<fpage>1116</fpage>
<lpage>1118</lpage>
<pub-id pub-id-type="pmid">15169703</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Engberg</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Shimizu</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Nordin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lindström</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Iyo</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naïve schizophrenic patients</article-title>
<source/>BMC Psychiatry
          <year>2005</year>
<volume>5</volume>
<fpage>6</fpage>
<pub-id pub-id-type="pmid">15683541</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bustillo</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Rowland</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Mullins</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Qualls</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hammond</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Brooks</surname>
<given-names>WM</given-names>
</name>
<name>
<surname>Lauriello</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title><sup>1</sup>H-MRS at 4 T in minimally treated early schizophrenia</article-title>
<source/>Mol Psychiatry
          <year>2009</year>
<volume>15</volume>
<fpage>629</fpage>
<lpage>636</lpage>
<pub-id pub-id-type="pmid">19918243</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de la Fuente-Sandoval</surname>
<given-names>C</given-names>
</name>
<name>
<surname>León-Ortiz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Favila</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Stephano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mamo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ramírez-Bermúdez</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Graff-Guerrero</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis</article-title>
<source/>Neuropsychopharmacology
          <year>2011</year>
<volume>36</volume>
<fpage>1781</fpage>
<lpage>1791</lpage>
<pub-id pub-id-type="pmid">21508933</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandt</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Unschuld</surname>
<given-names>PG</given-names>
</name>
<name>
<surname>Pradhan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>IA</given-names>
</name>
<name>
<surname>Churchill</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Hua</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Ross</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>van Zijl</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Edden</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Margolis</surname>
<given-names>RL</given-names>
</name>
</person-group>
<article-title>Age-related changes in anterior cingulate cortex glutamate in schizophrenia: a <sup>1</sup>H MRS study at 7 T</article-title>
<source/>Schizophr Res
          <year>2016</year>
<volume>172</volume>
<issue>1–3</issue>
<fpage>101</fpage>
<lpage>105</lpage>
<pub-id pub-id-type="pmid">26925800</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Merritt</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Egerton</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kempton</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>PK</given-names>
</name>
</person-group>
<article-title>Nature of glutamate alterations in schizophrenia: a meta-analysis of proton magnetic resonance spectroscopy studies</article-title>
<source/>JAMA Psychiatry
          <year>2016</year>
<volume>73</volume>
<issue>7</issue>
<fpage>665</fpage>
<lpage>674</lpage>
<pub-id pub-id-type="pmid">27304221</pub-id>
</element-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tayoshi</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Sumitani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shibuya-Tayoshi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Numata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iga</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nakataki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ueno</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ohmori</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (<sup>1</sup>H-MRS)</article-title>
<source/>Schizophr Res
          <year>2009</year>
<volume>108</volume>
<fpage>69</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">19097753</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohrmann</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Siegmund</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Suslow</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Spitzberg</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kersting</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arolt</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Heindel</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pfleiderer</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study</article-title>
<source/>Schizophr Res
          <year>2005</year>
<volume>73</volume>
<issue>2–3</issue>
<fpage>153</fpage>
<lpage>157</lpage>
<pub-id pub-id-type="pmid">15653258</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chiappelli</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rowland</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Wijtenburg</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Muellerklein</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Tagamets</surname>
<given-names>M</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Gaston</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kochunov</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>LE</given-names>
</name>
</person-group>
<article-title>Evaluation of <italic>myo</italic>-inositol as a potential biomarker for depression in schizophrenia</article-title>
<source/>Neuropsychopharmacology
          <year>2015</year>
<volume>40</volume>
<issue>9</issue>
<fpage>2157</fpage>
<lpage>2164</lpage>
<pub-id pub-id-type="pmid">25722115</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wijtenburg</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Korenic</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Gaston</surname>
<given-names>FE</given-names>
</name>
<name>
<surname>Ndubuizu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chiappelli</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Savransky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Kochunov</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Rowland</surname>
<given-names>LM</given-names>
</name>
</person-group>
<article-title>Altered glutamate and regional cerebral blood flow levels in schizophrenia: a <sup>1</sup>H-MRS and pCASL study</article-title>
<source/>Neuropsychopharmacology
          <year>2017</year>
<volume>42</volume>
<issue>2</issue>
<fpage>562</fpage>
<lpage>571</lpage>
<pub-id pub-id-type="pmid">27562377</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schaller</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Mekle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Kunz</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Net increase of lactate and glutamate concentration in activated human visual cortex detected with magnetic resonance spectroscopy at 7 T</article-title>
<source/>J Neurosci Res
          <year>2013</year>
<volume>91</volume>
<issue>8</issue>
<fpage>1076</fpage>
<lpage>1083</lpage>
<pub-id pub-id-type="pmid">23378234</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mangia</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tkác</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Van de Moortele</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Maraviglia</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Uğurbil</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Sustained neuronal activation raises oxidative metabolism to a new steady-state level: evidence from <sup>1</sup>H NMR spectroscopy in the human visual cortex</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2007</year>
<volume>27</volume>
<fpage>1055</fpage>
<lpage>1063</lpage>
<pub-id pub-id-type="pmid">17033694</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonnay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
</person-group>
<article-title>How energy metabolism supports cerebral function: insights from <sup>13</sup>C magnetic resonance studies in vivo</article-title>
<source/>Front Neurosci
          <year>2017</year>
<volume>11</volume>
<fpage>288</fpage>
<pub-id pub-id-type="pmid">28603480</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Taylor</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Neufeld</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Densmore</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rajakumar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Osuch</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Théberge</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Functional magnetic resonance spectroscopy of glutamate in schizophrenia and major depressive disorder: anterior cingulate activity during a color-word Stroop task</article-title>
<source/>NPJ Schizophr
          <year>2015</year>
<volume>1</volume>
<fpage>15028</fpage>
<pub-id pub-id-type="pmid">27336037</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farzan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Barr</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Levinson</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Fitzgerald</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Daskalakis</surname>
<given-names>ZJ</given-names>
</name>
</person-group>
<article-title>Evidence for gamma inhibition deficits in the dorsolateral prefrontal cortex of patients with schizophrenia</article-title>
<source/>Brain
          <year>2010</year>
<volume>133</volume>
<issue>Pt 5</issue>
<fpage>1505</fpage>
<lpage>1514</lpage>
<pub-id pub-id-type="pmid">20350936</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandal</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Edgar</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Klook</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Siegel</surname>
<given-names>SJ</given-names>
</name>
</person-group>
<article-title>Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia</article-title>
<source/>Neuropharmacology
          <year>2012</year>
<volume>62</volume>
<issue>3</issue>
<fpage>1504</fpage>
<lpage>1518</lpage>
<pub-id pub-id-type="pmid">21349276</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akbarian</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Potkin</surname>
<given-names>SG</given-names>
</name>
<name>
<surname>Hagman</surname>
<given-names>JO</given-names>
</name>
<name>
<surname>Tafazzoli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bunney</surname>
<given-names>WE</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Jones</surname>
<given-names>EG</given-names>
</name>
</person-group>
<article-title>Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics</article-title>
<source/>Arch Gen Psychiatry
          <year>1995</year>
<volume>52</volume>
<issue>4</issue>
<fpage>258</fpage>
<lpage>266</lpage>
<pub-id pub-id-type="pmid">7702443</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Volk</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Pierri</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>DA</given-names>
</name>
</person-group>
<article-title>Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia</article-title>
<source/>Arch Gen Psychiatry
          <year>2000</year>
<volume>57</volume>
<issue>3</issue>
<fpage>237</fpage>
<lpage>245</lpage>
<pub-id pub-id-type="pmid">10711910</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goto</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Yoshimura</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moriya</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kakeda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Ikenouchi-Sugita</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Umene-Nakano</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hayashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Oonari</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Korogi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nakamura</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Reduction of brain gamma-aminobutyric acid (GABA) concentrations in early-stage schizophrenia patients: 3T Proton MRS study</article-title>
<source/>Schizophr Res
          <year>2009</year>
<volume>112</volume>
<issue>1–3</issue>
<fpage>192</fpage>
<lpage>193</lpage>
<pub-id pub-id-type="pmid">19464152</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tayoshi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Nakataki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sumitani</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Taniguchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Shibuya-Tayoshi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Numata</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Iga</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ueno</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Harada</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ohmori</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>GABA concentration in schizophrenia patients and the effects of antipsychotic medication: a proton magnetic resonance spectroscopy study</article-title>
<source/>Schizophr Res
          <year>2010</year>
<volume>117</volume>
<issue>1</issue>
<fpage>83</fpage>
<lpage>91</lpage>
<pub-id pub-id-type="pmid">20022731</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kegeles</surname>
<given-names>LS</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Stanford</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Girgis</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ojeil</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Gil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Slifstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Abi-Dargham</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lisanby</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Shungu</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Elevated prefrontal cortex γ-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy</article-title>
<source/>Arch Gen Psychiatry
          <year>2012</year>
<volume>69</volume>
<issue>5</issue>
<fpage>449</fpage>
<lpage>459</lpage>
<pub-id pub-id-type="pmid">22213769</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowland</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Kontson</surname>
<given-names>K</given-names>
</name>
<name>
<surname>West</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Edden</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wijtenburg</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Holcomb</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>In vivo measurements of glutamate, GABA, and NAAG in schizophrenia</article-title>
<source/>Schizophr Bull
          <year>2013</year>
<volume>39</volume>
<issue>5</issue>
<fpage>1096</fpage>
<lpage>1104</lpage>
<pub-id pub-id-type="pmid">23081992</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowland</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Wijtenburg</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>RP</given-names>
</name>
<name>
<surname>Chiappelli</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nugent</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Nisonger</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Korenic</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Kochunov</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>LE</given-names>
</name>
</person-group>
<article-title>Medial frontal GABA is lower in older schizophrenia: a MEGA-PRESS with macromolecule suppression study</article-title>
<source/>Mol Psychiatry
          <year>2016</year>
<volume>21</volume>
<issue>2</issue>
<fpage>198</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">25824298</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de la Fuente-Sandoval</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reyes-Madrigal</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>León-Ortiz</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rodríguez-Mayoral</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Solís-Vivanco</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Favila</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Graff-Guerrero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shungu</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Cortico-striatal GABAergic and glutamatergic dysregulations in subjects at ultra-high risk for psychosis investigated with proton magnetic resonance spectroscopy</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2015</year>
<volume>19</volume>
<issue>3</issue>
<fpage>pyv105</fpage>
<pub-id pub-id-type="pmid">26364273</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marenco</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Meyer</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>S</given-names>
</name>
<name>
<surname>van der Veen</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>DeJong</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Barnett</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Apud</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Dickinson</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Weinberger</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Berman</surname>
<given-names>KF</given-names>
</name>
</person-group>
<article-title>Prefrontal GABA levels measured with magnetic resonance spectroscopy in patients with psychosis and unaffected siblings</article-title>
<source/>Am J Psychiatry
          <year>2016</year>
<volume>173</volume>
<issue>5</issue>
<fpage>527</fpage>
<lpage>534</lpage>
<pub-id pub-id-type="pmid">26806873</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ongür</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Prescot</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>McCarthy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Renshaw</surname>
<given-names>PF</given-names>
</name>
</person-group>
<article-title>Elevated gamma-aminobutyric acid levels in chronic schizophrenia</article-title>
<source/>Biol Psychiatry
          <year>2010</year>
<volume>68</volume>
<issue>7</issue>
<fpage>667</fpage>
<lpage>670</lpage>
<pub-id pub-id-type="pmid">20598290</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marsman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mandl</surname>
<given-names>RC</given-names>
</name>
<name>
<surname>Klomp</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Bohlken</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Boer</surname>
<given-names>VO</given-names>
</name>
<name>
<surname>Andreychenko</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cahn</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Luijten</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Hulshoff Pol</surname>
<given-names>HE</given-names>
</name>
</person-group>
<article-title>GABA and glutamate in schizophrenia: a 7 T <sup>1</sup>H-MRS study</article-title>
<source/>Neuroimage Clin
          <year>2014</year>
<volume>6</volume>
<fpage>398</fpage>
<lpage>407</lpage>
<pub-id pub-id-type="pmid">25379453</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thakkar</surname>
<given-names>KN</given-names>
</name>
<name>
<surname>Rösler</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wijnen</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Boer</surname>
<given-names>VO</given-names>
</name>
<name>
<surname>Klomp</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Cahn</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Neggers</surname>
<given-names>SF</given-names>
</name>
</person-group>
<article-title>7T proton magnetic resonance spectroscopy of gamma-aminobutyric acid, glutamate, and glutamine reveals altered concentrations in patients with schizophrenia and healthy siblings</article-title>
<source/>Biol Psychiatry
          <year>2016</year>
<volume>81</volume>
<issue>6</issue>
<fpage>525</fpage>
<lpage>535</lpage>
<pub-id pub-id-type="pmid">27316853</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
<name>
<surname>Trabesinger</surname>
<given-names>AH</given-names>
</name>
<name>
<surname>Kirsten-Krüger</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lauer</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Dydak</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Hell</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Holsboer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Boesiger</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cuénod</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo</article-title>
<source/>Eur J Neurosci
          <year>2000</year>
<volume>12</volume>
<issue>10</issue>
<fpage>3721</fpage>
<lpage>3728</lpage>
<pub-id pub-id-type="pmid">11029642</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsuzawa</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia</article-title>
<source/>Antioxid Redox Signal
          <year>2011</year>
<volume>15</volume>
<issue>7</issue>
<fpage>2057</fpage>
<lpage>2065</lpage>
<pub-id pub-id-type="pmid">20712400</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gysin</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kraftsik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sandell</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bovet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Chappuis</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Conus</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Deppen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Preisig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Steullet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tosic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Werge</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cuénod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
</person-group>
<article-title>Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2007</year>
<volume>104</volume>
<issue>42</issue>
<fpage>16621</fpage>
<lpage>16626</lpage>
<pub-id pub-id-type="pmid">17921251</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tosic</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ott</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Barral</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bovet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Deppen</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gheorghita</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Matthey</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Parnas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Preisig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Saraga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Solida</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Timm</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Werge</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Cuénod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
</person-group>
<article-title>Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene</article-title>
<source/>Am J Hum Genet
          <year>2006</year>
<volume>79</volume>
<issue>3</issue>
<fpage>586</fpage>
<lpage>592</lpage>
<pub-id pub-id-type="pmid">16909399</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mekle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Alameda</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jenni</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Schaller</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Conus</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
</person-group>
<article-title>Genetic polymorphism associated prefrontal glutathione and its coupling with brain glutamate and peripheral redox status in early psychosis</article-title>
<source/>Schizophr Bull
          <year>2016</year>
<volume>42</volume>
<issue>5</issue>
<fpage>1185</fpage>
<lpage>1196</lpage>
<pub-id pub-id-type="pmid">27069063</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Terpstra</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vaughan</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Ugurbil</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>KO</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Validation of glutathione quantitation from STEAM spectra against edited <sup>1</sup>H NMR spectroscopy at 4T: application to schizophrenia</article-title>
<source/>MAGMA
          <year>2005</year>
<volume>18</volume>
<issue>5</issue>
<fpage>276</fpage>
<lpage>282</lpage>
<pub-id pub-id-type="pmid">16320094</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Monin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Baumann</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Griffa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Xin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mekle</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fournier</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Butticaz</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Klaey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cabungcal</surname>
<given-names>J-H</given-names>
</name>
<name>
<surname>Steullet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ferrari</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Thiran</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Hagmann</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Conus</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
</person-group>
<article-title>Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<issue>7</issue>
<fpage>827</fpage>
<lpage>838</lpage>
<pub-id pub-id-type="pmid">25155877</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>XH</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>BY</given-names>
</name>
<name>
<surname>Ugurbil</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W</given-names>
</name>
</person-group>
<article-title>In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences</article-title>
<source/>Proc Natl Acad Sci USA
          <year>2015</year>
<volume>112</volume>
<issue>9</issue>
<fpage>2876</fpage>
<lpage>2881</lpage>
<pub-id pub-id-type="pmid">25730862</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lukas</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Shinn</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Yuksel</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Öngür</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Redox dysregulation in schizophrenia revealed by in vivo NAD<sup>+</sup>/NADH measurement</article-title>
<source/>Schizophr Bull
          <year>2017</year>
<volume>43</volume>
<issue>1</issue>
<fpage>197</fpage>
<lpage>204</lpage>
<pub-id pub-id-type="pmid">27665001</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clay</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Sillivan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Konradi</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction and pathology in bipolar disorder and schizophrenia</article-title>
<source/>Int J Dev Neurosci
          <year>2011</year>
<volume>29</volume>
<issue>3</issue>
<fpage>311</fpage>
<lpage>324</lpage>
<pub-id pub-id-type="pmid">20833242</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuksel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Tegin</surname>
<given-names>C</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ahat</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Ongur</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Phosphorus magnetic resonance spectroscopy studies in schizophrenia</article-title>
<source/>J Psychiatr Res
          <year>2015</year>
<volume>68</volume>
<fpage>157</fpage>
<lpage>166</lpage>
<pub-id pub-id-type="pmid">26228415</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Thida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sehovic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lukas</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>BM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Ongür</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>In vivo evidence for cerebral bioenergetic abnormalities in schizophrenia measured using <sup>31</sup>P magnetization transfer spectroscopy</article-title>
<source/>JAMA Psychiatry
          <year>2014</year>
<volume>71</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>27</lpage>
<pub-id pub-id-type="pmid">24196348</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rowland</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Pradhan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Korenic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wijtenburg</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Edden</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>PB</given-names>
</name>
</person-group>
<article-title>Elevated brain lactate in schizophrenia: a 7 T magnetic resonance spectroscopy study</article-title>
<source/>Transl Psychiatry
          <year>2016</year>
<volume>6</volume>
<issue>11</issue>
<fpage>e967</fpage>
<pub-id pub-id-type="pmid">27898072</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Regenold</surname>
<given-names>WT</given-names>
</name>
<name>
<surname>Phatak</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marano</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Sassan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Conley</surname>
<given-names>RR</given-names>
</name>
<name>
<surname>Kling</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis</article-title>
<source/>Biol Psychiatry
          <year>2009</year>
<volume>65</volume>
<issue>6</issue>
<fpage>489</fpage>
<lpage>494</lpage>
<pub-id pub-id-type="pmid">19103439</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iltis</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Koski</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Eberly</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Nelson</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Deelchand</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Valette</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ugurbil</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>KO</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>PG</given-names>
</name>
</person-group>
<article-title>Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized 1H MRS study</article-title>
<source/>NMR Biomed
          <year>2009</year>
<volume>22</volume>
<issue>7</issue>
<fpage>737</fpage>
<lpage>744</lpage>
<pub-id pub-id-type="pmid">19338025</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Kloet</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Joëls</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Holsboer</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Stress and the brain: from adaptation to disease</article-title>
<source/>Nat Rev Neurosci
          <year>2005</year>
<volume>6</volume>
<issue>6</issue>
<fpage>463</fpage>
<lpage>475</lpage>
<pub-id pub-id-type="pmid">15891777</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Leuner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shors</surname>
<given-names>TJ</given-names>
</name>
</person-group>
<article-title>Stress, anxiety, and dendritic spines: what are the connections?</article-title>
<source/>Neuroscience
          <year>2013</year>
<volume>251</volume>
<fpage>108</fpage>
<lpage>119</lpage>
<pub-id pub-id-type="pmid">22522470</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiavone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jaquet</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Trabace</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>KH</given-names>
</name>
</person-group>
<article-title>Severe life stress and oxidative stress in the brain: from animal models to human pathology</article-title>
<source/>Antioxid Redox Signal
          <year>2013</year>
<volume>18</volume>
<issue>12</issue>
<fpage>1475</fpage>
<lpage>1490</lpage>
<pub-id pub-id-type="pmid">22746161</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fone</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Porkess</surname>
<given-names>MV</given-names>
</name>
</person-group>
<article-title>Behavioural and neurochemical effects of post-weaning social isolation in rodents-relevance to developmental neuropsychiatric disorders</article-title>
<source/>Neurosci Biobehav Rev
          <year>2008</year>
<volume>32</volume>
<issue>6</issue>
<fpage>1087</fpage>
<lpage>1102</lpage>
<pub-id pub-id-type="pmid">18423591</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Rompala</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cowell</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Nakazawa</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Social isolation exacerbates schizophrenia-like phenotypes via oxidative stress in cortical interneurons</article-title>
<source/>Biol Psychiatry
          <year>2013</year>
<volume>73</volume>
<issue>10</issue>
<fpage>1024</fpage>
<lpage>1034</lpage>
<pub-id pub-id-type="pmid">23348010</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ieraci</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mallei</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Popoli</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Social isolation stress induces anxious-depressive-like behavior and alterations of neuroplasticity-related genes in adult male mice</article-title>
<source/>Neural Plast
          <year>2016</year>
<volume>2016</volume>
<fpage>6212983</fpage>
<pub-id pub-id-type="pmid">26881124</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Napolitano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schubert</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Porkess</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Auer</surname>
<given-names>DP</given-names>
</name>
</person-group>
<article-title>In vivo neurometabolic profiling to characterize the effects of social isolation and ketamine-induced NMDA antagonism: a rodent study at 7.0 T</article-title>
<source/>Schizophr Bull
          <year>2014</year>
<volume>40</volume>
<issue>3</issue>
<fpage>566</fpage>
<lpage>574</lpage>
<pub-id pub-id-type="pmid">23671195</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haj-Mirzaian</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Amiri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Amini-Khoei</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Rahimi-Balaei</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kordjazy</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Olson</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Rastegar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Naserzadeh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Marzban</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dehpour</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Hosseini</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Samiei</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mehr</surname>
<given-names>SE</given-names>
</name>
</person-group>
<article-title>Attenuation of oxidative and nitrosative stress in cortical area associates with antidepressant-like effects of tropisetron in male mice following social isolation stress</article-title>
<source/>Brain Res Bull
          <year>2016</year>
<volume>124</volume>
<fpage>150</fpage>
<lpage>163</lpage>
<pub-id pub-id-type="pmid">27129671</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Dietz</surname>
<given-names>K</given-names>
</name>
<name>
<surname>DeLoyht</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Pedre</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Kelkar</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Kaur</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Vialou</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lobo</surname>
<given-names>MK</given-names>
</name>
<name>
<surname>Dietz</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Nestler</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Dupree</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Casaccia</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Impaired adult myelination in the prefrontal cortex of socially isolated mice</article-title>
<source/>Nat Neurosci
          <year>2012</year>
<volume>15</volume>
<issue>12</issue>
<fpage>1621</fpage>
<lpage>1623</lpage>
<pub-id pub-id-type="pmid">23143512</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Makinodan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Corfas</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>A critical period for social experience-dependent oligodendrocyte maturation and myelination</article-title>
<source/>Science
          <year>2012</year>
<volume>337</volume>
<issue>6100</issue>
<fpage>1357</fpage>
<lpage>1360</lpage>
<pub-id pub-id-type="pmid">22984073</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schiavone</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sorce</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Dubois-Dauphin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jaquet</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Colaianna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zotti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cuomo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Trabace</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>KH</given-names>
</name>
</person-group>
<article-title>Involvement of NOX2 in the development of behavioral and pathologic alterations in isolated rats</article-title>
<source/>Biol Psychiatry
          <year>2009</year>
<volume>66</volume>
<issue>4</issue>
<fpage>384</fpage>
<lpage>392</lpage>
<pub-id pub-id-type="pmid">19559404</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corcoba</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
</person-group>
<article-title>Social isolation stress and chronic glutathione deficiency have a common effect on the glutamine-to-glutamate ratio and myo-inositol concentration in the mouse frontal cortex</article-title>
<source/>J Neurochem
          <year>2017</year>
<volume>142</volume>
<issue>5</issue>
<fpage>767</fpage>
<lpage>775</lpage>
<pub-id pub-id-type="pmid">28664650</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gapp</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Corcoba</surname>
<given-names>A</given-names>
</name>
<name>
<surname>van Steenwyk</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Mansuy</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
</person-group>
<article-title>Brain metabolic alterations in mice subjected to postnatal traumatic stress and in their offspring</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2017</year>
<volume>37</volume>
<issue>7</issue>
<fpage>2423</fpage>
<lpage>2432</lpage>
<pub-id pub-id-type="pmid">27604311</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vernon</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>So</surname>
<given-names>PW</given-names>
</name>
<name>
<surname>Lythgoe</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Chege</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Kapur</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Longitudinal in vivo maturational changes of metabolites in the prefrontal cortex of rats exposed to polyinosinic-polycytidylic acid in utero</article-title>
<source/>Eur Neuropsychopharmacol
          <year>2015</year>
<volume>25</volume>
<issue>12</issue>
<fpage>2210</fpage>
<lpage>2220</lpage>
<pub-id pub-id-type="pmid">26475576</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
<name>
<surname>Cabungcal</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Frank</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Steullet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Redox dysregulation, neurodevelopment, and schizophrenia</article-title>
<source/>Curr Opin Neurobiol
          <year>2009</year>
<volume>19</volume>
<fpage>220</fpage>
<lpage>230</lpage>
<pub-id pub-id-type="pmid">19481443</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Dieter</surname>
<given-names>MZ</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Shertzer</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Nebert</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Dalton</surname>
<given-names>TP</given-names>
</name>
</person-group>
<article-title>Initial characterization of the glutamate–cysteine ligase modifier subunit Gclm(/) knockout mouse. Novel model system for a severely compromised oxidative stress response</article-title>
<source/>J Biol Chem
          <year>2002</year>
<volume>277</volume>
<issue>51</issue>
<fpage>49446</fpage>
<lpage>49452</lpage>
<pub-id pub-id-type="pmid">12384496</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Curran</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Nebert</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>KV</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Vorhees</surname>
<given-names>CV</given-names>
</name>
</person-group>
<article-title>Effect of chronic glutathione deficiency on the behavioral phenotype of <italic>Gclm</italic> / knockout mice</article-title>
<source/>Neurotoxicol Teratol
          <year>2012</year>
<volume>34</volume>
<issue>4</issue>
<fpage>450</fpage>
<lpage>457</lpage>
<pub-id pub-id-type="pmid">22580179</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corcoba</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Steullet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
<name>
<surname>Van de Looij</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Monin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
</person-group>
<article-title>Glutathione deficit affects the integrity and function of the fimbria/fornix and anterior commissure in mice: relevance for schizophrenia</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2016</year>
<volume>19</volume>
<issue>3</issue>
<fpage>1</fpage>
<lpage>11</lpage>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabungcal</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Steullet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kraftsik</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
</person-group>
<article-title>Early-life insults impair parvalbumin interneurons via oxidative stress: reversal by <italic>N</italic>-acetylcysteine</article-title>
<source/>Biol Psychiatry
          <year>2013</year>
<volume>73</volume>
<issue>6</issue>
<fpage>574</fpage>
<lpage>582</lpage>
<pub-id pub-id-type="pmid">23140664</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
<name>
<surname>Kulak</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gholam-Razaee</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
</person-group>
<article-title><italic>N</italic>-Acetylcysteine normalizes neurochemical changes in the glutathione-deficient schizophrenia mouse model during development</article-title>
<source/>Biol Psychiatry
          <year>2012</year>
<volume>71</volume>
<issue>11</issue>
<fpage>1006</fpage>
<lpage>1014</lpage>
<pub-id pub-id-type="pmid">21945305</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brenner</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kondziella</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Håberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sonnewald</surname>
<given-names>U</given-names>
</name>
</person-group>
<article-title>Impaired glutamine metabolism in NMDA receptor hypofunction induced by MK801</article-title>
<source/>J Neurochem
          <year>2005</year>
<volume>94</volume>
<issue>6</issue>
<fpage>1594</fpage>
<lpage>1603</lpage>
<pub-id pub-id-type="pmid">16045441</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Steullet</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cabungcal</surname>
<given-names>J-H</given-names>
</name>
<name>
<surname>Monin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Dwir</surname>
<given-names>D</given-names>
</name>
<name>
<surname>O’Donnell</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Cuenod</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
</person-group>
<article-title>Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology?</article-title>
<source/>Schizophr Res
          <year>2016</year>
<volume>176</volume>
<issue>1</issue>
<fpage>41</fpage>
<lpage>51</lpage>
<pub-id pub-id-type="pmid">25000913</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phensy</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Driskill</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lindquist</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Jeevakumar</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Kroener</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Antioxidant treatment in male mice prevents mitochondrial and synaptic changes in an NMDA receptor dysfunction model of schizophrenia</article-title>
<source/>eNeuro
          <year>2017</year>
<pub-id pub-id-type="doi">10.1523/ENEURO.0081-17.2017</pub-id>
<pub-id pub-id-type="pmid">28819639</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lerma</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Morales</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Vicente</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Herreras</surname>
<given-names>O</given-names>
</name>
</person-group>
<article-title>Glutamate receptors of the kainate type and synaptic transmission</article-title>
<source/>Trends Neurosci
          <year>1997</year>
<volume>20</volume>
<fpage>9</fpage>
<lpage>12</lpage>
<pub-id pub-id-type="pmid">9004411</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kirkwood</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>HK</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>MF</given-names>
</name>
</person-group>
<article-title>Co-regulation of long-term potentiation and experience-dependent synaptic plasticity in visual cortex by age and experience</article-title>
<source/>Nature
          <year>1995</year>
<volume>375</volume>
<fpage>328</fpage>
<lpage>331</lpage>
<pub-id pub-id-type="pmid">7753198</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Conn</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Pin</surname>
<given-names>JP</given-names>
</name>
</person-group>
<article-title>Pharmacology and functions of metabotropic glutamate receptors</article-title>
<source/>Annu Rev Pharmacol Toxicol
          <year>1997</year>
<volume>37</volume>
<fpage>205</fpage>
<lpage>237</lpage>
<pub-id pub-id-type="pmid">9131252</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Harris</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Saleh</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Edden</surname>
<given-names>RA</given-names>
</name>
</person-group>
<article-title>Edited <sup>1</sup>H magnetic resonance spectroscopy in vivo: methods and metabolites</article-title>
<source/>Magn Reson Med
          <year>2017</year>
<volume>77</volume>
<issue>4</issue>
<fpage>1377</fpage>
<lpage>1389</lpage>
<pub-id pub-id-type="pmid">28150876</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bergeron</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Coyle</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Tsai</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Greene</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>NAAG reduces NMDA receptor current in CA1 hippocampal pyramidal neurons of acute slices and dissociated neurons</article-title>
<source/>Neuropsychopharmacology
          <year>2005</year>
<volume>30</volume>
<issue>1</issue>
<fpage>7</fpage>
<lpage>16</lpage>
<pub-id pub-id-type="pmid">15354184</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neale</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Bzdega</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wroblewska</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title><italic>N</italic>-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system</article-title>
<source/>J Neurochem
          <year>2000</year>
<volume>75</volume>
<issue>2</issue>
<fpage>443</fpage>
<lpage>452</lpage>
<pub-id pub-id-type="pmid">10899918</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Becker</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lodder</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gieselmann</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Eckhardt</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Molecular characterization of <italic>N</italic>-acetylaspartylglutamate synthetase</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<issue>38</issue>
<fpage>29156</fpage>
<lpage>29164</lpage>
<pub-id pub-id-type="pmid">20643647</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Collard</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Stroobant</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Lamosa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kapanda</surname>
<given-names>CN</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Muccioli</surname>
<given-names>GG</given-names>
</name>
<name>
<surname>Poupaert</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Opperdoes</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Van Schaftingen</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Molecular identification of <italic>N</italic>-acetylaspartylglutamate synthase and β-citrylglutamate synthase</article-title>
<source/>J Biol Chem
          <year>2010</year>
<volume>285</volume>
<issue>39</issue>
<fpage>29826</fpage>
<lpage>29833</lpage>
<pub-id pub-id-type="pmid">20657015</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neale</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title><italic>N</italic>-Acetylaspartylglutamate is an agonist at mGluR3 in vivo and in vitro</article-title>
<source/>J Neurochem
          <year>2011</year>
<volume>119</volume>
<issue>5</issue>
<fpage>891</fpage>
<lpage>895</lpage>
<pub-id pub-id-type="pmid">21740441</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ramadan</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cappiello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wroblewska</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Bzdega</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>NAAG inhibits KCl-induced [<sup>3</sup>H]-GABA release via mGluR3, cAMP, PKA and L-type calcium conductance</article-title>
<source/>Eur J Neurosci
          <year>2001</year>
<volume>13</volume>
<issue>2</issue>
<fpage>340</fpage>
<lpage>346</lpage>
<pub-id pub-id-type="pmid">11168538</pub-id>
</element-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romei</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Raiteri</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Raiteri</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Glycine release is regulated by metabotropic glutamate receptors sensitive to mGluR2/3 ligands and activated by <italic>N</italic>-acetylaspartylglutamate (NAAG)</article-title>
<source/>Neuropharmacology
          <year>2013</year>
<volume>66</volume>
<fpage>311</fpage>
<lpage>316</lpage>
<pub-id pub-id-type="pmid">22659408</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zuo</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bzdega</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Olszewski</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Moffett</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Effects of <italic>N</italic>-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia</article-title>
<source/>J Biol Chem
          <year>2012</year>
<volume>287</volume>
<issue>26</issue>
<fpage>21773</fpage>
<lpage>21782</lpage>
<pub-id pub-id-type="pmid">22570482</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Olszewski</surname>
<given-names>RT1</given-names>
</name>
<name>
<surname>Janczura</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Ball</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Madore</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lavin</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Der</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Hark</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Farago</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Profaci</surname>
<given-names>CP</given-names>
</name>
<name>
<surname>Bzdega</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Neale</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia</article-title>
<source/>Transl Psychiatry
          <year>2012</year>
<volume>2</volume>
<fpage>e145</fpage>
<pub-id pub-id-type="pmid">22850437</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nudmamud</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Reynolds</surname>
<given-names>GP</given-names>
</name>
</person-group>
<article-title><italic>N</italic>-Acetylaspartate and <italic>N</italic>-acetylaspartylglutamate deficits in superior temporal cortex in schizophrenia and bipolar disorder: a postmortem study</article-title>
<source/>Biol Psychiatry
          <year>2003</year>
<volume>53</volume>
<issue>12</issue>
<fpage>1138</fpage>
<lpage>1141</lpage>
<pub-id pub-id-type="pmid">12814865</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schousboe</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Transport and metabolism of glutamate and GABA in neurons are glial cells</article-title>
<source/>Int Rev Neurobiol
          <year>1981</year>
<volume>22</volume>
<fpage>1</fpage>
<lpage>45</lpage>
<pub-id pub-id-type="pmid">6115823</pub-id>
</element-citation>
</ref>
<ref id="CR103">
<label>103.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fonnum</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Glutamate: a neurotransmitter in mammalian brain</article-title>
<source/>J Neurochem
          <year>1984</year>
<volume>42</volume>
<fpage>1</fpage>
<lpage>11</lpage>
<pub-id pub-id-type="pmid">6139418</pub-id>
</element-citation>
</ref>
<ref id="CR104">
<label>104.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Derouiche</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Frotscher</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Astroglial processes around identified glutamatergic synapses contain glutamine synthetase: evidence for transmitter degradation</article-title>
<source/>Brain Res
          <year>1991</year>
<volume>552</volume>
<issue>2</issue>
<fpage>346</fpage>
<lpage>350</lpage>
<pub-id pub-id-type="pmid">1680531</pub-id>
</element-citation>
</ref>
<ref id="CR105">
<label>105.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonnay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Poirot</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Just</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Clerc</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Rainer</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
</person-group>
<article-title>Astrocytic and neuronal oxidative metabolism are coupled to the rate of glutamate-glutamine cycle in the tree shrew visual cortex</article-title>
<source/>Glia
          <year>2017</year>
<volume>66</volume>
<issue>3</issue>
<fpage>477</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="pmid">29120073</pub-id>
</element-citation>
</ref>
<ref id="CR106">
<label>106.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bauer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Meador-Woodruff</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>McCullumsmith</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia</article-title>
<source/>Schizophr Res
          <year>2010</year>
<volume>117</volume>
<issue>1</issue>
<fpage>92</fpage>
<lpage>98</lpage>
<pub-id pub-id-type="pmid">19716271</pub-id>
</element-citation>
</ref>
<ref id="CR107">
<label>107.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lucas</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Drummond</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Meador-Woodruff</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>McCullumsmith</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia</article-title>
<source/>Schizophr Res
          <year>2013</year>
<volume>144</volume>
<issue>1–3</issue>
<fpage>1</fpage>
<lpage>8</lpage>
<pub-id pub-id-type="pmid">23356950</pub-id>
</element-citation>
</ref>
<ref id="CR108">
<label>108.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sullivan</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>O’Donovan</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>McCullumsmith</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Ramsey</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Defects in bioenergetic coupling in schizophrenia</article-title>
<source/>Biol Psychiatry
          <year>2017</year>
<pub-id pub-id-type="doi">10.1016/j.biopsych.2017.10.014</pub-id>
<pub-id pub-id-type="pmid">29217297</pub-id>
</element-citation>
</ref>
<ref id="CR109">
<label>109.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McCullumsmith</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>O’Donovan</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Drummond</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Benesh</surname>
<given-names>FS</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lauriat</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Meador-Woodruff</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons?</article-title>
<source/>Mol Psychiatry
          <year>2016</year>
<volume>21</volume>
<issue>6</issue>
<fpage>823</fpage>
<lpage>830</lpage>
<pub-id pub-id-type="pmid">26416546</pub-id>
</element-citation>
</ref>
<ref id="CR110">
<label>110.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Donovan</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Hasselfeld</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Simmons</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Roussos</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Meador-Woodruff</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>McCullumsmith</surname>
<given-names>RE</given-names>
</name>
</person-group>
<article-title>Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia</article-title>
<source/>Transl Psychiatry
          <year>2015</year>
<volume>5</volume>
<fpage>e579</fpage>
<pub-id pub-id-type="pmid">26057049</pub-id>
</element-citation>
</ref>
<ref id="CR111">
<label>111.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Spangaro</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bosia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Zanoletti</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bechi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mariachiara</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Pirovano</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bramanti</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Smeraldi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Cavallaro</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia</article-title>
<source/>Pharmacogenomics
          <year>2014</year>
<volume>15</volume>
<issue>7</issue>
<fpage>925</fpage>
<lpage>932</lpage>
<pub-id pub-id-type="pmid">24956246</pub-id>
</element-citation>
</ref>
<ref id="CR112">
<label>112.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malthankar-Phatak</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>de Lanerolle</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Eid</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>DD</given-names>
</name>
<name>
<surname>Behar</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Lai</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Differential glutamate dehydrogenase (GDH) activity profile in patients with temporal lobe epilepsy</article-title>
<source/>Epilepsia
          <year>2006</year>
<volume>47</volume>
<issue>8</issue>
<fpage>1292</fpage>
<lpage>1299</lpage>
<pub-id pub-id-type="pmid">16922873</pub-id>
</element-citation>
</ref>
<ref id="CR113">
<label>113.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gluck</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Haroutunian</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients</article-title>
<source/>Am J Psychiatry
          <year>2002</year>
<volume>159</volume>
<issue>7</issue>
<fpage>1165</fpage>
<lpage>1173</lpage>
<pub-id pub-id-type="pmid">12091195</pub-id>
</element-citation>
</ref>
<ref id="CR114">
<label>114.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burbaeva</surname>
<given-names>GSh</given-names>
</name>
<name>
<surname>Boksha</surname>
<given-names>IS</given-names>
</name>
<name>
<surname>Tereshkina</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Savushkina</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Starodubtseva</surname>
<given-names>LI</given-names>
</name>
<name>
<surname>Turishcheva</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Mukaetova-Ladinska</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Systemic neurochemical alterations in schizophrenic brain: glutamate metabolism in focus</article-title>
<source/>Neurochem Res
          <year>2007</year>
<volume>32</volume>
<issue>9</issue>
<fpage>1434</fpage>
<lpage>1444</lpage>
<pub-id pub-id-type="pmid">17440811</pub-id>
</element-citation>
</ref>
<ref id="CR115">
<label>115.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lander</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Lewandowski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Provenzano</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Mingote</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chornyy</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Frigerio</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Maechler</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Kaphzan</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Small</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Rayport</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gaisler-Salomon</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Glutamate dehydrogenase-deficient mice display schizophrenia-like behavioral abnormalities and CA1-specific hippocampal dysfunction</article-title>
<source/>Schizophr Bull
          <year>2018</year>
<pub-id pub-id-type="doi">10.1093/schbul/sby011</pub-id>
</element-citation>
</ref>
<ref id="CR116">
<label>116.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Boumezbeur</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mason</surname>
<given-names>GF</given-names>
</name>
<name>
<surname>de Graaf</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Behar</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Cline</surname>
<given-names>GW</given-names>
</name>
<name>
<surname>Shulman</surname>
<given-names>GI</given-names>
</name>
<name>
<surname>Rothman</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>KF</given-names>
</name>
</person-group>
<article-title>Altered brain mitochondrial metabolism in healthy aging as assessed by in vivo magnetic resonance spectroscopy</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2010</year>
<volume>30</volume>
<issue>1</issue>
<fpage>211</fpage>
<lpage>221</lpage>
<pub-id pub-id-type="pmid">19794401</pub-id>
</element-citation>
</ref>
<ref id="CR117">
<label>117.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Horváth</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Janka</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Mirnics</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Analyzing schizophrenia by DNA microarrays</article-title>
<source/>Biol Psychiatry
          <year>2011</year>
<volume>69</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>162</lpage>
<pub-id pub-id-type="pmid">20801428</pub-id>
</element-citation>
</ref>
<ref id="CR118">
<label>118.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martins-de-Souza</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Proteomics as a tool for understanding schizophrenia</article-title>
<source/>Clin Psychopharmacol Neurosci
          <year>2011</year>
<volume>9</volume>
<issue>3</issue>
<fpage>95</fpage>
<lpage>101</lpage>
<pub-id pub-id-type="pmid">23430140</pub-id>
</element-citation>
</ref>
<ref id="CR119">
<label>119.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Prabakaran</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Swatton</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Ryan</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Huffaker</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>JT</given-names>
</name>
<name>
<surname>Griffin</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Wayland</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Freeman</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Dudbridge</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lilley</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Karp</surname>
<given-names>NA</given-names>
</name>
<name>
<surname>Hester</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tkachev</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Mimmack</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Yolken</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Webster</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Torrey</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Bahn</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress</article-title>
<source/>Mol Psychiatry
          <year>2004</year>
<volume>9</volume>
<issue>7</issue>
<fpage>684</fpage>
<lpage>697</lpage>
<pub-id pub-id-type="pmid">15098003</pub-id>
</element-citation>
</ref>
<ref id="CR120">
<label>120.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonçalves</surname>
<given-names>VF</given-names>
</name>
<name>
<surname>Andreazza</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Kennedy</surname>
<given-names>JL</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction in schizophrenia: an evolutionary perspective</article-title>
<source/>Hum Genet
          <year>2015</year>
<volume>134</volume>
<issue>1</issue>
<fpage>13</fpage>
<lpage>21</lpage>
<pub-id pub-id-type="pmid">25312050</pub-id>
</element-citation>
</ref>
<ref id="CR121">
<label>121.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kung</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>RC</given-names>
</name>
</person-group>
<article-title>Mitochondrial pathology in human schizophrenic striatum: a postmortem ultrastructural study</article-title>
<source/>Synapse
          <year>1999</year>
<volume>31</volume>
<issue>1</issue>
<fpage>67</fpage>
<lpage>75</lpage>
<pub-id pub-id-type="pmid">10025685</pub-id>
</element-citation>
</ref>
<ref id="CR122">
<label>122.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Uranova</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Orlovskaya</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vikhreva</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Zimina</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kolomeets</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Vostrikov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Rachmanova</surname>
<given-names>V</given-names>
</name>
</person-group>
<article-title>Electron microscopy of oligodendroglia in severe mental illness</article-title>
<source/>Brain Res Bull
          <year>2001</year>
<volume>55</volume>
<issue>5</issue>
<fpage>597</fpage>
<lpage>610</lpage>
<pub-id pub-id-type="pmid">11576756</pub-id>
</element-citation>
</ref>
<ref id="CR123">
<label>123.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Farkas</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Jaeger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Christman</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Regional brain glucose metabolism in chronic schizophrenia. A positron emission transaxial tomographic study</article-title>
<source/>Arch Gen Psychiatry
          <year>1984</year>
<volume>41</volume>
<issue>3</issue>
<fpage>293</fpage>
<lpage>300</lpage>
<pub-id pub-id-type="pmid">6608333</pub-id>
</element-citation>
</ref>
<ref id="CR124">
<label>124.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacobsen</surname>
<given-names>LK</given-names>
</name>
<name>
<surname>Hamburger</surname>
<given-names>SD</given-names>
</name>
<name>
<surname>Van Horn</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Vaituzis</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Frazier</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>CT</given-names>
</name>
<name>
<surname>Lenane</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Rapoport</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Zametkin</surname>
<given-names>AJ</given-names>
</name>
</person-group>
<article-title>Cerebral glucose metabolism in childhood onset schizophrenia</article-title>
<source/>Psychiatry Res
          <year>1997</year>
<volume>75</volume>
<issue>3</issue>
<fpage>131</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="pmid">9437771</pub-id>
</element-citation>
</ref>
<ref id="CR125">
<label>125.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Minzenberg</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Laird</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Thelen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>CS</given-names>
</name>
<name>
<surname>Glahn</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>Meta-analysis of 41 functional neuroimaging studies of executive function in schizophrenia</article-title>
<source/>Arch Gen Psychiatry
          <year>2009</year>
<volume>66</volume>
<issue>8</issue>
<fpage>811</fpage>
<lpage>822</lpage>
<pub-id pub-id-type="pmid">19652121</pub-id>
</element-citation>
</ref>
<ref id="CR126">
<label>126.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hill</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mann</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Laws</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Stephenson</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Nimmo-Smith</surname>
<given-names>I</given-names>
</name>
<name>
<surname>McKenna</surname>
<given-names>PJ</given-names>
</name>
</person-group>
<article-title>Hypofrontality in schizophrenia: a meta-analysis of functional imaging studies</article-title>
<source/>Acta Psychiatr Scand
          <year>2004</year>
<volume>110</volume>
<issue>4</issue>
<fpage>243</fpage>
<lpage>256</lpage>
<pub-id pub-id-type="pmid">15352925</pub-id>
</element-citation>
</ref>
<ref id="CR127">
<label>127.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Venâncio</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Félix</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Almeida</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Coutinho</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Antunes</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Peixoto</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Summavielle</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Acute ketamine impairs mitochondrial function and promotes superoxide dismutase activity in the rat brain</article-title>
<source/>Anesth Analg
          <year>2015</year>
<volume>120</volume>
<issue>2</issue>
<fpage>320</fpage>
<lpage>328</lpage>
<pub-id pub-id-type="pmid">25427286</pub-id>
</element-citation>
</ref>
<ref id="CR128">
<label>128.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Oliveira</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Fraga</surname>
<given-names>DB</given-names>
</name>
<name>
<surname>De Luca</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Canever</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ghedim</surname>
<given-names>FV</given-names>
</name>
<name>
<surname>Matos</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Streck</surname>
<given-names>EL</given-names>
</name>
<name>
<surname>Quevedo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zugno</surname>
<given-names>AI</given-names>
</name>
</person-group>
<article-title>Behavioral changes and mitochondrial dysfunction in a rat model of schizophrenia induced by ketamine</article-title>
<source/>Metab Brain Dis
          <year>2011</year>
<volume>26</volume>
<issue>1</issue>
<fpage>69</fpage>
<lpage>77</lpage>
<pub-id pub-id-type="pmid">21331561</pub-id>
</element-citation>
</ref>
<ref id="CR129">
<label>129.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Möller</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Du Preez</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Viljoen</surname>
<given-names>FP</given-names>
</name>
<name>
<surname>Berk</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Emsley</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Harvey</surname>
<given-names>BH</given-names>
</name>
</person-group>
<article-title>Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or <italic>N</italic>-acetylcysteine</article-title>
<source/>Brain Behav Immun
          <year>2013</year>
<volume>30</volume>
<fpage>156</fpage>
<lpage>167</lpage>
<pub-id pub-id-type="pmid">23270677</pub-id>
</element-citation>
</ref>
<ref id="CR130">
<label>130.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moghaddam</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>BW</given-names>
</name>
</person-group>
<article-title>Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats</article-title>
<source/>Science
          <year>1998</year>
<volume>281</volume>
<issue>5381</issue>
<fpage>1349</fpage>
<lpage>1352</lpage>
<pub-id pub-id-type="pmid">9721099</pub-id>
</element-citation>
</ref>
<ref id="CR131">
<label>131.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sonnay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
<name>
<surname>Just</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Compartmentalised energy metabolism supporting glutamatergic neurotransmission in response to increased activity in the rat cerebral cortex: a <sup>13</sup>C MRS study in vivo at 14.1 T</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2016</year>
<volume>36</volume>
<issue>5</issue>
<fpage>928</fpage>
<lpage>940</lpage>
<pub-id pub-id-type="pmid">26823472</pub-id>
</element-citation>
</ref>
<ref id="CR132">
<label>132.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chowdhury</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Behar</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Rothman</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Sanacora</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title><sup>1</sup>H-[<sup>13</sup>C]-nuclear magnetic resonance spectroscopy measures of ketamine’s effect on amino acid neurotransmitter metabolism</article-title>
<source/>Biol Psychiatry
          <year>2012</year>
<volume>71</volume>
<issue>11</issue>
<fpage>1022</fpage>
<lpage>1025</lpage>
<pub-id pub-id-type="pmid">22169441</pub-id>
</element-citation>
</ref>
<ref id="CR133">
<label>133.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wolkin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jaeger</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Brodie</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Fowler</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rotrosen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gomez-Mont</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cancro</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography</article-title>
<source/>Am J Psychiatry
          <year>1985</year>
<volume>142</volume>
<issue>5</issue>
<fpage>564</fpage>
<lpage>571</lpage>
<pub-id pub-id-type="pmid">3872603</pub-id>
</element-citation>
</ref>
<ref id="CR134">
<label>134.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kaneko</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Sanganahalli</surname>
<given-names>BG</given-names>
</name>
<name>
<surname>Groman</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Coman</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Rich</surname>
<given-names>K</given-names>
</name>
<name>
<surname>de Graaf</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Hyder</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>Hypofrontality and posterior hyperactivity in early schizophrenia: imaging and behavior in a preclinical model</article-title>
<source/>Biol Psychiatry
          <year>2017</year>
<volume>81</volume>
<issue>6</issue>
<fpage>503</fpage>
<lpage>513</lpage>
<pub-id pub-id-type="pmid">27450031</pub-id>
</element-citation>
</ref>
<ref id="CR135">
<label>135.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weissman</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Dam</surname>
<given-names>M</given-names>
</name>
<name>
<surname>London</surname>
<given-names>ED</given-names>
</name>
</person-group>
<article-title>Alterations in local cerebral glucose utilization induced by phencyclidine</article-title>
<source/>Brain Res
          <year>1987</year>
<volume>435</volume>
<fpage>29</fpage>
<lpage>40</lpage>
<pub-id pub-id-type="pmid">3427457</pub-id>
</element-citation>
</ref>
<ref id="CR136">
<label>136.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miyamoto</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Leipzig</surname>
<given-names>JN</given-names>
</name>
<name>
<surname>Lieberman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>GE</given-names>
</name>
</person-group>
<article-title>Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice</article-title>
<source/>Neuropsychopharmacology
          <year>2000</year>
<volume>22</volume>
<fpage>400</fpage>
<lpage>412</lpage>
<pub-id pub-id-type="pmid">10700659</pub-id>
</element-citation>
</ref>
<ref id="CR137">
<label>137.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lahti</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Holcomb</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>Medoff</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Tamminga</surname>
<given-names>CA</given-names>
</name>
</person-group>
<article-title>Ketamine activates psychosis and alters limbic blood flow in schizophrenia</article-title>
<source/>Neuroreport
          <year>1995</year>
<volume>6</volume>
<issue>6</issue>
<fpage>869</fpage>
<lpage>872</lpage>
<pub-id pub-id-type="pmid">7612873</pub-id>
</element-citation>
</ref>
<ref id="CR138">
<label>138.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breier</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Malhotra</surname>
<given-names>AK</given-names>
</name>
<name>
<surname>Pinals</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Weisenfeld</surname>
<given-names>NI</given-names>
</name>
<name>
<surname>Pickar</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers</article-title>
<source/>Am J Psychiatry
          <year>1997</year>
<volume>154</volume>
<issue>6</issue>
<fpage>805</fpage>
<lpage>811</lpage>
<pub-id pub-id-type="pmid">9167508</pub-id>
</element-citation>
</ref>
<ref id="CR139">
<label>139.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vollenweider</surname>
<given-names>FX</given-names>
</name>
<name>
<surname>Leenders</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Oye</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Hell</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Angst</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET)</article-title>
<source/>Eur Neuropsychopharmacol
          <year>1997</year>
<volume>7</volume>
<issue>1</issue>
<fpage>25</fpage>
<lpage>38</lpage>
<pub-id pub-id-type="pmid">9088882</pub-id>
</element-citation>
</ref>
<ref id="CR140">
<label>140.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yuksel</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ravichandran</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Goldbach</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Thida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Dora</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Gelda</surname>
<given-names>J</given-names>
</name>
<name>
<surname>O’Connor</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sehovic</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Gruber</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ongur</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Abnormal high-energy phosphate molecule metabolism during regional brain activation in patients with bipolar disorder</article-title>
<source/>Mol Psychiatry
          <year>2015</year>
<volume>20</volume>
<issue>9</issue>
<fpage>1079</fpage>
<lpage>1084</lpage>
<pub-id pub-id-type="pmid">25754079</pub-id>
</element-citation>
</ref>
<ref id="CR141">
<label>141.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryan</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Collins</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Thakore</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia</article-title>
<source/>Am J Psychiatry
          <year>2003</year>
<volume>160</volume>
<issue>2</issue>
<fpage>284</fpage>
<lpage>289</lpage>
<pub-id pub-id-type="pmid">12562574</pub-id>
</element-citation>
</ref>
<ref id="CR142">
<label>142.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Egea</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Parellada</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Justicia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Garcia-Rizo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Esmatjes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Conget</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Glucose abnormalities in the siblings of people with schizophrenia</article-title>
<source/>Schizophr Res
          <year>2008</year>
<volume>103</volume>
<issue>1–3</issue>
<fpage>110</fpage>
<lpage>113</lpage>
<pub-id pub-id-type="pmid">18514487</pub-id>
</element-citation>
</ref>
<ref id="CR143">
<label>143.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fernandez-Egea</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Bernardo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Donner</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Conget</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Parellada</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Justicia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Esmatjes</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Garcia-Rizo</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kirkpatrick</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Metabolic profile of antipsychotic-naive individuals with non-affective psychosis</article-title>
<source/>Br J Psychiatry
          <year>2009</year>
<volume>194</volume>
<issue>5</issue>
<fpage>434</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="pmid">19407273</pub-id>
</element-citation>
</ref>
<ref id="CR144">
<label>144.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Konradi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Eaton</surname>
<given-names>M</given-names>
</name>
<name>
<surname>MacDonald</surname>
<given-names>ML</given-names>
</name>
<name>
<surname>Walsh</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Benes</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Heckers</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Molecular evidence for mitochondrial dysfunction in bipolar disorder</article-title>
<source/>Arch Gen Psychiatry
          <year>2004</year>
<volume>61</volume>
<issue>3</issue>
<fpage>300</fpage>
<lpage>308</lpage>
<pub-id pub-id-type="pmid">14993118</pub-id>
</element-citation>
</ref>
<ref id="CR145">
<label>145.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LT</given-names>
</name>
</person-group>
<article-title>Downregulation in components of the mitochondrial electron transport chain in the postmortem frontal cortex of subjects with bipolar disorder</article-title>
<source/>J Psychiatry Neurosci
          <year>2006</year>
<volume>31</volume>
<issue>3</issue>
<fpage>189</fpage>
<lpage>196</lpage>
<pub-id pub-id-type="pmid">16699605</pub-id>
</element-citation>
</ref>
<ref id="CR146">
<label>146.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tobe</surname>
<given-names>EH</given-names>
</name>
</person-group>
<article-title>Mitochondrial dysfunction, oxidative stress, and major depressive disorder</article-title>
<source/>Neuropsychiatr Dis Treat
          <year>2013</year>
<volume>9</volume>
<fpage>567</fpage>
<lpage>573</lpage>
<pub-id pub-id-type="pmid">23650447</pub-id>
</element-citation>
</ref>
<ref id="CR147">
<label>147.</label>
<mixed-citation publication-type="other">Siddiqui MF, Elwell C, Johnson MH (2016) Mitochondrial dysfunction in autism spectrum disorders. Autism Open Access 6(5)</mixed-citation>
</ref>
<ref id="CR148">
<label>148.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Radley</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Sisti</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Rocher</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>McCall</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Hof</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>McEwen</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>JH</given-names>
</name>
</person-group>
<article-title>Chronic behavioral stress induces apical dendritic reorganization in pyramidal neurons of the medial prefrontal cortex</article-title>
<source/>Neuroscience
          <year>2004</year>
<volume>125</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>6</lpage>
<pub-id pub-id-type="pmid">15051139</pub-id>
</element-citation>
</ref>
<ref id="CR149">
<label>149.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brown</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Henning</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wellman</surname>
<given-names>CL</given-names>
</name>
</person-group>
<article-title>Mild, short-term stress alters dendritic morphology in rat medial prefrontal cortex</article-title>
<source/>Cereb Cortex
          <year>2005</year>
<volume>15</volume>
<issue>11</issue>
<fpage>1714</fpage>
<lpage>1722</lpage>
<pub-id pub-id-type="pmid">15703248</pub-id>
</element-citation>
</ref>
<ref id="CR150">
<label>150.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liston</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Goldwater</surname>
<given-names>DS</given-names>
</name>
<name>
<surname>Radley</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Rocher</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Hof</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>McEwen</surname>
<given-names>BS</given-names>
</name>
</person-group>
<article-title>Stress-induced alterations in prefrontal cortical dendritic morphology predict selective impairments in perceptual attentional set-shifting</article-title>
<source/>J Neurosci
          <year>2006</year>
<volume>26</volume>
<issue>30</issue>
<fpage>7870</fpage>
<lpage>7874</lpage>
<pub-id pub-id-type="pmid">16870732</pub-id>
</element-citation>
</ref>
<ref id="CR151">
<label>151.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hermes</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duman</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Post-weaning chronic social isolation produces profound behavioral dysregulation with decreases in prefrontal cortex synaptic-associated protein expression in female rats</article-title>
<source/>Physiol Behav
          <year>2011</year>
<volume>104</volume>
<issue>2</issue>
<fpage>354</fpage>
<lpage>359</lpage>
<pub-id pub-id-type="pmid">21185848</pub-id>
</element-citation>
</ref>
<ref id="CR152">
<label>152.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sestito</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Trindade</surname>
<given-names>LB</given-names>
</name>
<name>
<surname>de Souza</surname>
<given-names>RG</given-names>
</name>
<name>
<surname>Kerbauy</surname>
<given-names>LN</given-names>
</name>
<name>
<surname>Iyomasa</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Rosa</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Effect of isolation rearing on the expression of AMPA glutamate receptors in the hippocampal formation</article-title>
<source/>J Psychopharmacol
          <year>2011</year>
<volume>25</volume>
<issue>12</issue>
<fpage>1720</fpage>
<lpage>1729</lpage>
<pub-id pub-id-type="pmid">20952455</pub-id>
</element-citation>
</ref>
<ref id="CR153">
<label>153.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gaskin</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Toledo-Rodriguez</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Alexander</surname>
<given-names>SP</given-names>
</name>
<name>
<surname>Fone</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>Down-regulation of hippocampal genes regulating dopaminergic, GABAergic, and glutamatergic function following combined neonatal phencyclidine and post-weaning social isolation of rats as a neurodevelopmental model for schizophrenia</article-title>
<source/>Int J Neuropsychopharmacol
          <year>2016</year>
<volume>19</volume>
<issue>11</issue>
<fpage>pyw062</fpage>
<pub-id pub-id-type="pmid">27382048</pub-id>
</element-citation>
</ref>
<ref id="CR154">
<label>154.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clark</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Doepke</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Filosa</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Wardle</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Meeker</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Pyne-Geithman</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title><italic>N</italic>-Acetylaspartate as a reservoir for glutamate</article-title>
<source/>Med Hypotheses
          <year>2006</year>
<volume>67</volume>
<issue>3</issue>
<fpage>506</fpage>
<lpage>512</lpage>
<pub-id pub-id-type="pmid">16730130</pub-id>
</element-citation>
</ref>
<ref id="CR155">
<label>155.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Francis</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Strande</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Markov</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Aspartoacylase supports oxidative energy metabolism during myelination</article-title>
<source/>J Cereb Blood Flow Metab
          <year>2012</year>
<volume>32</volume>
<issue>9</issue>
<fpage>1725</fpage>
<lpage>1736</lpage>
<pub-id pub-id-type="pmid">22617649</pub-id>
</element-citation>
</ref>
<ref id="CR156">
<label>156.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duarte</surname>
<given-names>JMN</given-names>
</name>
<name>
<surname>Do</surname>
<given-names>KQ</given-names>
</name>
<name>
<surname>Gruetter</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Longitudinal neurochemical modifications in the aging mouse brain measured in vivo by <sup>1</sup>H MRS</article-title>
<source/>Neurobiol Aging
          <year>2014</year>
<volume>35</volume>
<issue>7</issue>
<fpage>1660</fpage>
<lpage>1668</lpage>
<pub-id pub-id-type="pmid">24560998</pub-id>
</element-citation>
</ref>
<ref id="CR157">
<label>157.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Waddell</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Zanjanipour</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Pradhan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Welch</surname>
<given-names>EB</given-names>
</name>
<name>
<surname>Joers</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Avison</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Gore</surname>
<given-names>JC</given-names>
</name>
</person-group>
<article-title>Anterior cingulate and cerebellar GABA and Glu correlations measured by <sup>1</sup>H J-difference spectroscopy</article-title>
<source/>Magn Reson Imaging
          <year>2011</year>
<volume>29</volume>
<issue>1</issue>
<fpage>19</fpage>
<lpage>24</lpage>
<pub-id pub-id-type="pmid">20884148</pub-id>
</element-citation>
</ref>
<ref id="CR158">
<label>158.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kraguljac</surname>
<given-names>NV</given-names>
</name>
<name>
<surname>White</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Reid</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Lahti</surname>
<given-names>AC</given-names>
</name>
</person-group>
<article-title>Increased hippocampal glutamate and volumetric deficits in unmedicated patients with schizophrenia</article-title>
<source/>JAMA Psychiatry
          <year>2013</year>
<volume>70</volume>
<issue>12</issue>
<fpage>1294</fpage>
<lpage>1302</lpage>
<pub-id pub-id-type="pmid">24108440</pub-id>
</element-citation>
</ref>
<ref id="CR159">
<label>159.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Coughlin</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Tanaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Marsman</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bonekamp</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>PK</given-names>
</name>
<name>
<surname>Higgs</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Varvaris</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Edden</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Pomper</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schretlen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Barker</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Sawa</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Decoupling of <italic>N</italic>-acetyl-aspartate and glutamate within the dorsolateral prefrontal cortex in schizophrenia</article-title>
<source/>Curr Mol Med
          <year>2015</year>
<volume>15</volume>
<issue>2</issue>
<fpage>176</fpage>
<lpage>183</lpage>
<pub-id pub-id-type="pmid">25732147</pub-id>
</element-citation>
</ref>
<ref id="CR160">
<label>160.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Aoyama</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Théberge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Drost</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Manchanda</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Northcott</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Neufeld</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Menon</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Rajakumar</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pavlosky</surname>
<given-names>WF</given-names>
</name>
<name>
<surname>Densmore</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Schaefer</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Williamson</surname>
<given-names>PC</given-names>
</name>
</person-group>
<article-title>Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia</article-title>
<source/>Br J Psychiatry
          <year>2011</year>
<volume>198</volume>
<issue>6</issue>
<fpage>448</fpage>
<lpage>456</lpage>
<pub-id pub-id-type="pmid">21628707</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>